Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	semaphorin receptor activity	PLXNA3 PLXNA4 PLXNA2	1.09e-04	12	162	3	GO:0017154
GeneOntologyMolecularFunction	protein phosphatase 1 binding	LILRB1 PPP1R3C PPP1R3F PAWR	1.80e-04	35	162	4	GO:0008157
GeneOntologyBiologicalProcess	semaphorin-plexin signaling pathway	PLXNA3 SH3BP1 MEF2C SEMA4G PLXNA4 PLXNA2	3.01e-06	52	160	6	GO:0071526
GeneOntologyBiologicalProcess	protein depolymerization	EPS8 CARMIL2 MAP1B SH3BP1 SPECC1L NCKAP5L SPTBN5 KIF18B	1.70e-05	144	160	8	GO:0051261
GeneOntologyBiologicalProcess	olfactory nerve development	PLXNA3 CHD7 DMD	2.49e-05	8	160	3	GO:0021553
GeneOntologyBiologicalProcess	neuron projection morphogenesis	PLXNA3 MAP1B SRCIN1 MECP2 MEF2A MEF2C SEMA4G NLGN3 HMCN2 PLPPR4 GLI2 SLIT3 PLXNA4 KNDC1 MACF1 DMD GOLGA2 PLXNA2	5.26e-05	802	160	18	GO:0048812
GeneOntologyBiologicalProcess	plasma membrane bounded cell projection morphogenesis	PLXNA3 MAP1B SRCIN1 MECP2 MEF2A MEF2C SEMA4G NLGN3 HMCN2 PLPPR4 GLI2 SLIT3 PLXNA4 KNDC1 MACF1 DMD GOLGA2 PLXNA2	6.88e-05	819	160	18	GO:0120039
GeneOntologyBiologicalProcess	cell projection morphogenesis	PLXNA3 MAP1B SRCIN1 MECP2 MEF2A MEF2C SEMA4G NLGN3 HMCN2 PLPPR4 GLI2 SLIT3 PLXNA4 KNDC1 MACF1 DMD GOLGA2 PLXNA2	7.67e-05	826	160	18	GO:0048858
GeneOntologyBiologicalProcess	regulation of actin filament depolymerization	EPS8 CARMIL2 SH3BP1 SPECC1L SPTBN5	1.11e-04	61	160	5	GO:0030834
GeneOntologyBiologicalProcess	cranial nerve structural organization	PLXNA3 PLXNA4 DMD	1.24e-04	13	160	3	GO:0021604
GeneOntologyBiologicalProcess	negative regulation of protein-containing complex disassembly	EPS8 CARMIL2 MAP1B UBQLN4 SPECC1L SPTBN5	1.30e-04	100	160	6	GO:0043242
GeneOntologyBiologicalProcess	regulation of protein-containing complex disassembly	EPS8 CARMIL2 MAP1B UBQLN4 SH3BP1 SPECC1L SPTBN5	1.34e-04	144	160	7	GO:0043244
GeneOntologyBiologicalProcess	cell morphogenesis	PLXNA3 EPS8 MAP1B SRCIN1 MECP2 MEF2A MEF2C SEMA4G NLGN3 HMCN2 PLPPR4 GLI2 SLIT3 PLXNA4 KNDC1 MACF1 FGD5 DMD TAL1 GOLGA2 PLXNA2 BRWD1	1.41e-04	1194	160	22	GO:0000902
GeneOntologyBiologicalProcess	actin filament depolymerization	EPS8 CARMIL2 SH3BP1 SPECC1L SPTBN5	1.61e-04	66	160	5	GO:0030042
GeneOntologyBiologicalProcess	supramolecular fiber organization	EPS8 EPPK1 CARMIL2 MAP1B ARHGEF5 SH3BP1 SPECC1L NEB NCKAP5L MECP2 MEF2A MEF2C SPTBN5 SLC9A1 SORBS3 PAWR KIF18B CORO7 GOLGA2	1.62e-04	957	160	19	GO:0097435
GeneOntologyBiologicalProcess	regulation of protein depolymerization	EPS8 CARMIL2 MAP1B SH3BP1 SPECC1L SPTBN5	1.70e-04	105	160	6	GO:1901879
GeneOntologyBiologicalProcess	regulation of cytoskeleton organization	PLXNA3 TPR EPS8 CARMIL2 MAP1B ARHGEF5 SH3BP1 SPECC1L NEB MECP2 MEF2C SPTBN5 SLC9A1 SORBS3	1.74e-04	579	160	14	GO:0051493
GeneOntologyBiologicalProcess	olfactory nerve morphogenesis	PLXNA3 DMD	1.78e-04	3	160	2	GO:0021627
GeneOntologyBiologicalProcess	cell morphogenesis involved in neuron differentiation	PLXNA3 MAP1B SRCIN1 MEF2A MEF2C SEMA4G NLGN3 HMCN2 PLPPR4 GLI2 SLIT3 PLXNA4 KNDC1 MACF1 GOLGA2 PLXNA2	2.41e-04	748	160	16	GO:0048667
GeneOntologyBiologicalProcess	positive regulation of axonogenesis	PLXNA3 MAP1B PLXNA4 MACF1 GOLGA2 PLXNA2	2.65e-04	114	160	6	GO:0050772
GeneOntologyBiologicalProcess	regulation of organelle organization	TOM1L2 PLXNA3 TPR EPS8 EXOSC10 TBC1D15 CARMIL2 MAP1B RTEL1 ARHGEF5 TOM1L1 UBQLN4 SH3BP1 AMBRA1 SPECC1L NEB MECP2 MEF2C SPTBN5 SLC9A1 SORBS3 MKI67 TAL1	2.82e-04	1342	160	23	GO:0033043
GeneOntologyBiologicalProcess	sodium ion export across plasma membrane	SLC9A1 ATP1A4 ATP4A	2.88e-04	17	160	3	GO:0036376
GeneOntologyCellularComponent	anchoring junction	AKAP6 CDCA3 EPPK1 CARMIL2 MYLK ARHGEF5 SH3BP1 AMBRA1 SRCIN1 GIT2 SPECC1L CBL SLC9A1 IGF2R ARVCF PARD6A AJM1 NECTIN2 SORBS3 ANO7 LRRC7 DMD	7.45e-06	976	163	22	GO:0070161
GeneOntologyCellularComponent	cell leading edge	EPS8 PDE4A CARMIL2 MYLK KNSTRN SH3BP1 SRCIN1 SLC9A1 KCNB1 PARD6A MACF1 FGD5 DMD USH2A MTSS2	9.13e-06	500	163	15	GO:0031252
GeneOntologyCellularComponent	semaphorin receptor complex	PLXNA3 PLXNA4 PLXNA2	1.26e-04	13	163	3	GO:0002116
GeneOntologyCellularComponent	ruffle	EPS8 PDE4A CARMIL2 KNSTRN PARD6A MACF1 FGD5 MTSS2	2.19e-04	206	163	8	GO:0001726
GeneOntologyCellularComponent	symmetric, GABA-ergic, inhibitory synapse	NLGN3 NLGN4X	3.59e-04	4	163	2	GO:0098983
GeneOntologyCellularComponent	ciliary transition zone	KIAA1549 SPTBN5 CEP131 TOPORS USH2A	4.31e-04	81	163	5	GO:0035869
GeneOntologyCellularComponent	lamellipodium	CARMIL2 MYLK SH3BP1 SRCIN1 SLC9A1 FGD5 DMD MTSS2	4.58e-04	230	163	8	GO:0030027
GeneOntologyCellularComponent	photoreceptor connecting cilium	KIAA1549 SPTBN5 TOPORS USH2A	5.31e-04	48	163	4	GO:0032391
GeneOntologyCellularComponent	cell-cell junction	AKAP6 CDCA3 EPPK1 CARMIL2 MYLK SH3BP1 SPECC1L SLC9A1 ARVCF PARD6A AJM1 NECTIN2 LRRC7	7.62e-04	591	163	13	GO:0005911
GeneOntologyCellularComponent	photoreceptor cell cilium	MAP1B KIAA1549 SPTBN5 ATP1A4 TOPORS USH2A	7.84e-04	139	163	6	GO:0097733
GeneOntologyCellularComponent	asymmetric, glutamatergic, excitatory synapse	NLGN3 NLGN4X PLXNA4	8.35e-04	24	163	3	GO:0098985
GeneOntologyCellularComponent	9+0 non-motile cilium	MAP1B KIAA1549 SPTBN5 ATP1A4 TOPORS USH2A	1.29e-03	153	163	6	GO:0097731
GeneOntologyCellularComponent	microtubule plus-end	KNSTRN NCKAP5L KIF18B	1.32e-03	28	163	3	GO:0035371
GeneOntologyCellularComponent	leading edge membrane	EPS8 PDE4A KCNB1 MACF1 FGD5 USH2A MTSS2	1.33e-03	210	163	7	GO:0031256
GeneOntologyCellularComponent	ruffle membrane	EPS8 PDE4A MACF1 FGD5 MTSS2	1.58e-03	108	163	5	GO:0032587
GeneOntologyCellularComponent	axon	EPS8 MAP1B DTNA SRCIN1 GIT2 CBL PGR HMCN2 KCNB1 PTPRN PARD6A PAWR LRRC7 DMD USH2A UNC80	1.66e-03	891	163	16	GO:0030424
HumanPheno	Lack of spontaneous play	MECP2 NLGN3 NLGN4X	6.81e-06	4	62	3	HP:0000721
HumanPheno	Abnormal play	MECP2 NLGN3 NLGN4X	6.81e-06	4	62	3	HP:5200104
HumanPheno	Inflexible adherence to routines	MECP2 NLGN3 NLGN4X	3.35e-05	6	62	3	HP:0000732
HumanPheno	Insistence on sameness	MECP2 NLGN3 NLGN4X	3.35e-05	6	62	3	HP:5200130
Domain	SPIN/Ssty	SPIN1 SPIN2A SPIN2B	5.43e-06	5	154	3	IPR003671
Domain	Spin-Ssty	SPIN1 SPIN2A SPIN2B	5.43e-06	5	154	3	PF02513
Domain	DEAH_ATP_HELICASE	RTEL1 YTHDC2 CHD7 CHD5 ERCC6L2	1.44e-05	38	154	5	PS00690
Domain	Plexin_cytopl	PLXNA3 PLXNA4 PLXNA2	4.45e-05	9	154	3	PF08337
Domain	Plexin_cytoplasmic_RasGAP_dom	PLXNA3 PLXNA4 PLXNA2	4.45e-05	9	154	3	IPR013548
Domain	Plexin	PLXNA3 PLXNA4 PLXNA2	4.45e-05	9	154	3	IPR031148
Domain	AIP3_C	SRCIN1 KIAA1217	6.75e-05	2	154	2	IPR022782
Domain	AIP3	SRCIN1 KIAA1217	6.75e-05	2	154	2	PF03915
Domain	DUF3827	KIAA1549 KIAA1549L	6.75e-05	2	154	2	PF12877
Domain	DUF3827	KIAA1549 KIAA1549L	6.75e-05	2	154	2	IPR024606
Domain	SPIN-2	SPIN2A SPIN2B	6.75e-05	2	154	2	IPR029564
Domain	Semap_dom	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.18e-04	31	154	4	IPR001627
Domain	SEMA	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.18e-04	31	154	4	PS51004
Domain	Sema	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.18e-04	31	154	4	SM00630
Domain	Sema	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.18e-04	31	154	4	PF01403
Domain	Plexin_repeat	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.34e-04	32	154	4	IPR002165
Domain	SPEC	AKAP6 SPTBN5 MACF1 DMD	1.34e-04	32	154	4	SM00150
Domain	PSI	PLXNA3 SEMA4G PLXNA4 PLXNA2	1.34e-04	32	154	4	PF01437
Domain	Spectrin/alpha-actinin	AKAP6 SPTBN5 MACF1 DMD	1.34e-04	32	154	4	IPR018159
Domain	DNA/RNA_helicase_DEAH_CS	RTEL1 CHD7 CHD5 ERCC6L2	1.91e-04	35	154	4	IPR002464
Domain	CH	SPECC1L SPTBN5 EHBP1L1 MACF1 DMD	1.98e-04	65	154	5	SM00033
Domain	TOM1	TOM1L2 TOM1L1	2.02e-04	3	154	2	IPR014645
Domain	CH	SPECC1L SPTBN5 EHBP1L1 MACF1 DMD	2.81e-04	70	154	5	PF00307
Domain	-	SPECC1L SPTBN5 EHBP1L1 MACF1 DMD	3.00e-04	71	154	5	1.10.418.10
Domain	CH	SPECC1L SPTBN5 EHBP1L1 MACF1 DMD	3.42e-04	73	154	5	PS50021
Domain	CH-domain	SPECC1L SPTBN5 EHBP1L1 MACF1 DMD	3.87e-04	75	154	5	IPR001715
Domain	HJURP_C	MEF2A MEF2C	4.01e-04	4	154	2	IPR022102
Domain	MADS_MEF2-like	MEF2A MEF2C	4.01e-04	4	154	2	IPR033896
Domain	HJURP_C	MEF2A MEF2C	4.01e-04	4	154	2	PF12347
Domain	PSI	PLXNA3 SEMA4G PLXNA4 PLXNA2	4.67e-04	44	154	4	IPR016201
Domain	Znf_ZZ	DTNA TADA2A DMD	4.83e-04	19	154	3	IPR000433
Domain	ZnF_ZZ	DTNA TADA2A DMD	4.83e-04	19	154	3	SM00291
Domain	PSI	PLXNA3 SEMA4G PLXNA4 PLXNA2	5.54e-04	46	154	4	SM00423
Domain	Nlgn	NLGN3 NLGN4X	6.65e-04	5	154	2	IPR000460
Domain	Rho_GTPase_activation_prot	PLXNA3 ARHGAP23 SH3BP1 PLXNA4 PLXNA2	8.07e-04	88	154	5	IPR008936
Domain	Spectrin	SPTBN5 MACF1 DMD	8.63e-04	23	154	3	PF00435
Domain	ACTININ_2	SPTBN5 MACF1 DMD	8.63e-04	23	154	3	PS00020
Domain	ACTININ_1	SPTBN5 MACF1 DMD	8.63e-04	23	154	3	PS00019
Domain	Actinin_actin-bd_CS	SPTBN5 MACF1 DMD	8.63e-04	23	154	3	IPR001589
Domain	-	EPPK1 MACF1	9.91e-04	6	154	2	3.90.1290.10
Domain	MADS_BOX_1	MEF2A MEF2C	9.91e-04	6	154	2	PS00350
Domain	GAT_dom	TOM1L2 TOM1L1	9.91e-04	6	154	2	IPR004152
Domain	-	TOM1L2 TOM1L1	9.91e-04	6	154	2	1.20.58.160
Domain	MADS	MEF2A MEF2C	9.91e-04	6	154	2	SM00432
Domain	GAT	TOM1L2 TOM1L1	9.91e-04	6	154	2	PS50909
Domain	SRF-TF	MEF2A MEF2C	9.91e-04	6	154	2	PF00319
Domain	MADS_BOX_2	MEF2A MEF2C	9.91e-04	6	154	2	PS50066
Domain	EF-hand_dom_typ1	DTNA DMD	9.91e-04	6	154	2	IPR015153
Domain	EF-hand_dom_typ2	DTNA DMD	9.91e-04	6	154	2	IPR015154
Domain	EF-hand_2	DTNA DMD	9.91e-04	6	154	2	PF09068
Domain	EF-hand_3	DTNA DMD	9.91e-04	6	154	2	PF09069
Domain	P-type_ATPase_IIC	ATP1A4 ATP4A	9.91e-04	6	154	2	IPR005775
Domain	GAT	TOM1L2 TOM1L1	9.91e-04	6	154	2	PF03127
Domain	Plectin	EPPK1 MACF1	1.38e-03	7	154	2	PF00681
Domain	TF_MADSbox	MEF2A MEF2C	1.38e-03	7	154	2	IPR002100
Domain	Plectin_repeat	EPPK1 MACF1	1.38e-03	7	154	2	IPR001101
Domain	CBM21_dom	PPP1R3C PPP1R3F	1.38e-03	7	154	2	IPR005036
Domain	CBM21	PPP1R3C PPP1R3F	1.38e-03	7	154	2	PS51159
Domain	PLEC	EPPK1 MACF1	1.38e-03	7	154	2	SM00250
Domain	CBM_21	PPP1R3C PPP1R3F	1.38e-03	7	154	2	PF03370
Domain	IPT	PLXNA3 PLXNA4 PLXNA2	1.39e-03	27	154	3	SM00429
Domain	Spectrin_repeat	SPTBN5 MACF1 DMD	1.72e-03	29	154	3	IPR002017
Domain	-	TRAF7 PLXNA3 AMBRA1 SEMA4G PLXNA4 CORO7 PLXNA2 SON BRWD1	1.80e-03	333	154	9	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	TRAF7 PLXNA3 AMBRA1 SEMA4G PLXNA4 CORO7 PLXNA2 SON BRWD1	1.88e-03	335	154	9	IPR015943
Domain	TIG	PLXNA3 PLXNA4 PLXNA2	2.09e-03	31	154	3	PF01833
Domain	SNF2_N	CHD7 CHD5 ERCC6L2	2.29e-03	32	154	3	IPR000330
Domain	IPT	PLXNA3 PLXNA4 PLXNA2	2.29e-03	32	154	3	IPR002909
Domain	SNF2_N	CHD7 CHD5 ERCC6L2	2.29e-03	32	154	3	PF00176
Domain	VHS	TOM1L2 TOM1L1	2.34e-03	9	154	2	PS50179
Domain	VHS	TOM1L2 TOM1L1	2.34e-03	9	154	2	PF00790
Domain	VHS	TOM1L2 TOM1L1	2.34e-03	9	154	2	SM00288
Domain	VHS_dom	TOM1L2 TOM1L1	2.34e-03	9	154	2	IPR002014
Pathway	REACTOME_SEMA3A_PLEXIN_REPULSION_SIGNALING_BY_INHIBITING_INTEGRIN_ADHESION	PLXNA3 PLXNA4 PLXNA2	4.07e-05	9	113	3	MM15030
Pathway	REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS	TPR NUP210 TOPORS NUP160	1.69e-04	35	113	4	M27320
Pathway	REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION	PLXNA3 PLXNA4 PLXNA2	1.71e-04	14	113	3	MM15029
Pathway	REACTOME_SEMA3A_PLEXIN_REPULSION_SIGNALING_BY_INHIBITING_INTEGRIN_ADHESION	PLXNA3 PLXNA4 PLXNA2	1.71e-04	14	113	3	M7578
Pathway	REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA	TPR NUP210 NUP160 NXF1	1.89e-04	36	113	4	M26974
Pathway	REACTOME_CRMPS_IN_SEMA3A_SIGNALING	PLXNA3 PLXNA4 PLXNA2	2.13e-04	15	113	3	MM15031
Pathway	REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION	PLXNA3 PLXNA4 PLXNA2	2.60e-04	16	113	3	M16498
Pathway	REACTOME_CRMPS_IN_SEMA3A_SIGNALING	PLXNA3 PLXNA4 PLXNA2	2.60e-04	16	113	3	M8245
Pathway	REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS	TPR NUP210 TOPORS NUP160	3.46e-04	42	113	4	MM15039
Pathway	REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA	TPR NUP210 NUP160 NXF1	3.80e-04	43	113	4	MM14609
Pathway	REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS	TPR NUP210 NUP160 NXF1	3.80e-04	43	113	4	M26975
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	TPR PDE4A BCLAF1 SH3BP1 CHD7 GIT2 SPECC1L PPFIA3 UBN2 NLGN3 IGF2R KCNB1 PLPPR4 ARVCF KIAA1217 ZNF516 PPP1R3F ANKRD17 MACF1 CEP131 LRRC7 FRMPD3 GOLGA2 DNMT1 MTSS2	4.82e-12	963	164	25	28671696
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	AKAP6 NCOA6 BCLAF1 TRIM35 SNX17 MARCHF6 KDM3B KIAA1549 AMBRA1 SRCIN1 LRRK1 ANKHD1 PLPPR4 HPS4 CHD5 ZNF516 SLIT3 ZBTB5 ANKRD17	9.19e-12	529	164	19	14621295
Pubmed	A human MAP kinase interactome.	TOM1L2 TPR TOM1L1 SPECC1L PLEKHA6 NEB CBL NCKAP5L MEF2C SLC9A1 KIAA1549L HPS4 ANKRD17 MACF1 YY1AP1 DUSP10 DMD GOLGA2	2.02e-11	486	164	18	20936779
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	TRAF7 ARHGAP23 KAT6A KIAA1549 AMBRA1 YTHDC2 PPFIA3 ANKHD1 NCKAP5L MECP2 FANCD2 HMCN2 CBY2 CHD5 PCSK6 ANKRD17 MACF1 TADA2A KIF18B TOPORS UNC80 SON BRWD1	3.21e-09	1116	164	23	31753913
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	TRAF7 EPS8 DTNA CHD7 GIT2 UBN2 TTC4 NCKAP5L RBM22 KIAA1217 ZNF516 MACF1 YY1AP1 CEP131 TOPORS GOLGA2 NXF1	3.23e-09	588	164	17	38580884
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	TOM1L2 EPS8 CARMIL2 MAP1B ARHGAP23 BCLAF1 KIAA1549 YTHDC2 SRCIN1 SPECC1L PLEKHA6 PPFIA3 OGDH MECP2 NLGN3 PLPPR4 ARVCF AJM1 KIAA1217 PLXNA4 KNDC1 MACF1 LRRC7 DMD CORO7 ATP5F1B	3.75e-09	1431	164	26	37142655
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	CDCA3 PAG1 ARHGAP23 SRCIN1 PLEKHA6 CBL SLC9A1 EHBP1L1 IGF2R ARVCF KIAA1217 NECTIN2 MACF1 LRRC7 JPT2 GOLGA2	1.28e-08	565	164	16	25468996
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	TRAF7 PLXNA3 NCOA6 PDE4A ANKS6 EPPK1 CLTCL1 KAT6A KDM3B AMBRA1 CARD10 LRRK1 ANKHD1 CASZ1 LPIN3 EHBP1L1 IGF2R ARVCF CHD5 ZNF516 SORBS3 CEP131	1.35e-08	1105	164	22	35748872
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	CDCA3 EPS8 ANKS6 CARMIL2 DTNA SNX17 KIAA1549 PLEKHA6 TTC4 SLC9A1 EHBP1L1 IGF2R NLGN4X ARVCF NECTIN2 PLXNA2	1.42e-08	569	164	16	30639242
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	TPR EXOSC10 EPPK1 MAP1B PSMC2 YTHDC2 CHD7 ANKHD1 IGF2R NUP210 MKI67 ANKRD17 MACF1 NUP160 NXF1 DNMT1 SON	1.51e-08	653	164	17	22586326
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	DNHD1 TPR NCOA6 EXOSC10 BCLAF1 NEB OGDH LPIN3 KIAA1549L MACF1 DMD	1.68e-08	234	164	11	36243803
Pubmed	Identification of novel Ack1-interacting proteins and Ack1 phosphorylated sites in mouse brain by mass spectrometry.	MAP1B ARHGAP23 SRCIN1 NLGN3 ARVCF AJM1 LRRC7	3.13e-08	67	164	7	29254152
Pubmed	A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response.	TPR MAP1B KIAA1217 MKI67 CEP131 PAWR JPT2 GOLGA2	9.70e-08	118	164	8	30979931
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	EPS8 PAG1 DTNA PLEKHA6 CBL IGF2R ARVCF PARD6A KIAA1217 NECTIN2 MACF1 DMD MTSS2	1.17e-07	421	164	13	36976175
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	AKAP6 NCOA6 RTEL1 KDM3B CHD7 GIT2 PPFIA3 CHD5 MACF1 UNC80	1.29e-07	225	164	10	12168954
Pubmed	MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.	TOM1L2 EPPK1 MAP1B BCLAF1 KNSTRN CHD7 CASZ1 GLI2 MKI67 MACF1 SDK1 SON	1.52e-07	358	164	12	32460013
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	MAP1B BCLAF1 SRCIN1 PLEKHA6 PPFIA3 KCNB1 AJM1 MACF1 LRRC7 BRWD1	1.65e-07	231	164	10	16452087
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	PERM1 CARD10 YTHDC2 ANKHD1 CASZ1 MKI67 PPP1R3F ANO7 CCDC17 TET3	1.79e-07	233	164	10	37704626
Pubmed	Chromosome assignment of four plexin A genes (Plxna1, Plxna2, Plxna3, Plxna4) in mouse, rat, Syrian hamster and Chinese hamster.	PLXNA3 PLXNA4 PLXNA2	4.10e-07	4	164	3	11306810
Pubmed	PlexinA polymorphisms mediate the developmental trajectory of human corpus callosum microstructure.	PLXNA3 PLXNA4 PLXNA2	4.10e-07	4	164	3	25518740
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	TPR EXOSC10 EPPK1 BCLAF1 YTHDC2 SPECC1L MECP2 RBM22 KIAA1217 CHD5 NUP210 MKI67 ANKRD17 PAWR TOPORS ATP4A NUP160 GOLGA2 NXF1 DNMT1 ATP5F1B	5.43e-07	1257	164	21	36526897
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	MAP1B RTEL1 DTNA TOM1L1 KAT6A SRCIN1 RBBP8NL UBN2 OGDH MEF2A CASZ1 NLGN3 SPIN1 GLI2 KIAA1217 LRRC27 NUP210 NECTIN2 KNDC1 ANKRD17 MACF1 LRRC7 TET3	5.82e-07	1489	164	23	28611215
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	CDCA3 DTNA SNX17 PSMC2 KIAA1549 PPFIA3 NCKAP5L FANCD2 IGF2R ARVCF PTPRN NUP210 NECTIN2 SORBS3 MKI67 CEP131 DUSP10 DMD DNMT1	5.97e-07	1049	164	19	27880917
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	ARHGAP23 RTEL1 ZFP28 PLEKHA6 UBN2 CASZ1 SEMA4G NLGN3 NUP210 MACF1 KLHL14 NUP160 UNC80	7.00e-07	493	164	13	15368895
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	TPR NCOA6 BCLAF1 KDM3B YTHDC2 CHD7 MECP2 FANCD2 ZNF516 SORBS3 MKI67 ANKRD17 YY1AP1 TOPORS DNMT1 SON	8.99e-07	774	164	16	15302935
Pubmed	Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells.	TPR NCOA6 EXOSC10 BCLAF1 YTHDC2 CHD7 MECP2 MKI67 JPT2 DNMT1	1.06e-06	283	164	10	30585729
Pubmed	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.	EPS8 TBC1D15 MAP1B KAT6A PSMC2 CARD10 SRCIN1 CBL MECP2 MEF2C EHBP1L1 ZNF516 CEP131 FGD5 SEZ6	1.06e-06	689	164	15	36543142
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	TPR EXOSC10 MAP1B ARHGAP23 SNX17 PSMC2 AMBRA1 CHD7 ANKHD1 RBM22 ARVCF MKI67 ANKRD17 MACF1 KIF18B CORO7 NUP160 NXF1 DNMT1 ATP5F1B SON	1.75e-06	1353	164	21	29467282
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	TPR EXOSC10 TBC1D15 EPPK1 MAP1B BCLAF1 YTHDC2 SPECC1L IGF2R NUP210 MKI67 MACF1 CEP131 PAWR NUP160 NXF1 ATP5F1B SON	1.84e-06	1024	164	18	24711643
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	MAP1B BCLAF1 YTHDC2 GIT2 SPECC1L ANKHD1 UBN2 RBM22 MKI67 ANKRD17 MACF1 KIF18B JPT2 NXF1 SON	1.95e-06	724	164	15	36232890
Pubmed	A transcriptional coregulator, SPIN·DOC, attenuates the coactivator activity of Spindlin1.	SPIN1 SPIN2A SPIN2B	2.04e-06	6	164	3	29061846
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	TPR NCOA6 EXOSC10 TBC1D15 MAP1B BCLAF1 KDM3B PSMC2 SPECC1L ANKHD1 UBN2 CBL DNMT1	2.30e-06	549	164	13	38280479
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	MAP1B ARHGAP23 ARHGEF5 KDM3B AMBRA1 YTHDC2 ANKHD1 LPIN3 ARVCF ANKRD17 YY1AP1 GOLGA2 NXF1 DNMT1	2.79e-06	650	164	14	38777146
Pubmed	Semaphorin-6A controls guidance of corticospinal tract axons at multiple choice points.	PLXNA3 PLXNA4 PLXNA2	3.55e-06	7	164	3	19063725
Pubmed	Increased proximal bifurcation of CA1 pyramidal apical dendrites in sema3A mutant mice.	PLXNA3 PLXNA4 PLXNA2	3.55e-06	7	164	3	19655386
Pubmed	An extracellular biochemical screen reveals that FLRTs and Unc5s mediate neuronal subtype recognition in the retina.	PLXNA3 SEMA4G PLXNA4 SDK1 PLXNA2	4.76e-06	52	164	5	26633812
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	TPR TBC1D15 UBQLN4 CHD7 RBBP8NL ANKHD1 ZNF516 ANKRD17 CEP131 TADA2A NXF1	5.26e-06	418	164	11	34709266
Pubmed	The expression of plexins during mouse embryogenesis.	PLXNA3 PLXNA4 PLXNA2	5.67e-06	8	164	3	15661641
Pubmed	Integration of opposing semaphorin guidance cues in cortical axons.	PLXNA3 PLXNA4 PLXNA2	5.67e-06	8	164	3	22368082
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	TOM1L2 MAP1B SNX17 SRCIN1 PLEKHA6 MECP2 KCNB1 AJM1 MACF1 LRRC7	6.48e-06	347	164	10	17114649
Pubmed	A directed protein interaction network for investigating intracellular signal transduction.	PLXNA3 EPS8 KNSTRN TOM1L1 UBQLN4 ZFP28 SHC3 PPP1R3C NECTIN2 MKI67 YY1AP1 HERC3 DUSP10 JPT2 GOLGA2 DNMT1 ATP5F1B SEZ6	6.65e-06	1124	164	18	21900206
Pubmed	The in vivo Interaction Landscape of Histones H3.1 and H3.3.	ARHGEF5 KAT6A KDM3B CHD7 UBN2 MECP2 CASZ1 SPIN1 CHD5 MKI67 KIF18B DNMT1 BRWD1	6.92e-06	608	164	13	36089195
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	PLXNA3 TRIM35 ZFP28 CBL MEF2A MEF2C PGR HOXB5 RBM22 GLI2 PCSK6 MKI67 MACF1 PLXNA2	7.49e-06	709	164	14	22988430
Pubmed	The role of neuropilins in cell signalling.	PLXNA3 PLXNA4 PLXNA2	8.47e-06	9	164	3	19909241
Pubmed	Using mouse models of autism spectrum disorders to study the neurotoxicology of gene-environment interactions.	MECP2 NLGN3 NLGN4X	8.47e-06	9	164	3	23010509
Pubmed	Expression of Robo/Slit and Semaphorin/Plexin/Neuropilin family members in the developing hypothalamic paraventricular and supraoptic nuclei.	PLXNA3 SLIT3 PLXNA4 PLXNA2	8.93e-06	28	164	4	18617019
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	TPR EXOSC10 MAP1B BCLAF1 KDM3B PSMC2 YTHDC2 ANKHD1 KIAA1217 MKI67 ANKRD17 MACF1 JPT2 DNMT1 ATP5F1B SON	9.77e-06	934	164	16	33916271
Pubmed	Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	RTEL1 TRIM35 KDM3B ANKHD1 CEP131 SON	1.04e-05	104	164	6	10470851
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NCOA6 KDM3B CHD7 PPFIA3 NEB CBL CASZ1 RBM22 EHBP1L1 ARVCF ZNF516 ANKRD17 FGD5	1.15e-05	638	164	13	31182584
Pubmed	Plexin A3 and plexin A4 convey semaphorin signals during facial nerve development.	PLXNA3 PLXNA4 PLXNA2	1.21e-05	10	164	3	18804103
Pubmed	Conserved molecular signatures of neurogenesis in the hippocampal subgranular zone of rodents and primates.	CDCA3 EPS8 SEMA4G PTPRN MKI67 PAWR DUSP10 PLXNA2 MTSS2 SEZ6	1.30e-05	376	164	10	24154525
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	NCOA6 CARMIL2 MAP1B ARHGEF5 KDM3B CBL NCKAP5L LPIN3 KIAA1217 NECTIN2 ANKRD17 MACF1 CEP131 DNMT1 MTSS2	1.54e-05	861	164	15	36931259
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	EXOSC10 TBC1D15 DTNA PSMC2 AMBRA1 YTHDC2 ANKHD1 NCKAP5L FANCD2 NUP210 ANKRD17 DUSP10 DMD CORO7 NUP160 ATP5F1B	1.63e-05	974	164	16	28675297
Pubmed	Variants in LRRC7 lead to intellectual disability, autism, aggression and abnormal eating behaviors.	NECTIN2 MACF1 LRRC7	1.65e-05	11	164	3	39256359
Pubmed	PlexinA1 signaling directs the segregation of proprioceptive sensory axons in the developing spinal cord.	PLXNA3 SEMA4G NECTIN2 PLXNA4 SDK1 PLXNA2	2.04e-05	117	164	6	17145500
Pubmed	On and off retinal circuit assembly by divergent molecular mechanisms.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	24179230
Pubmed	Deletion of Sema3a or plexinA1/plexinA3 causes defects in sensory afferent projections of statoacoustic ganglion neurons.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	23991118
Pubmed	Functional loss of semaphorin 3C and/or semaphorin 3D and their epistatic interaction with ret are critical to Hirschsprung disease liability.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	25839327
Pubmed	PLXNA1 and PLXNA3 cooperate to pattern the nasal axons that guide gonadotropin-releasing hormone neurons.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	31690636
Pubmed	Transcriptome profiling reveals expression signatures of cranial neural crest cells arising from different axial levels.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	28407732
Pubmed	Transmembrane semaphorin signalling controls laminar stratification in the mammalian retina.	PLXNA3 PLXNA4 PLXNA2	2.20e-05	12	164	3	21270798
Pubmed	Expression of Dnmt1, demethylase, MeCP2 and methylation of tumor-related genes in human gastric cancer.	MECP2 DNMT1	2.21e-05	2	164	2	15526354
Pubmed	Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice.	MEF2A MEF2C	2.21e-05	2	164	2	16469744
Pubmed	Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension.	MEF2A MEF2C	2.21e-05	2	164	2	25336633
Pubmed	Association Analysis of Noncoding Variants in Neuroligins 3 and 4X Genes with Autism Spectrum Disorder in an Italian Cohort.	NLGN3 NLGN4X	2.21e-05	2	164	2	27782075
Pubmed	Not all neuroligin 3 and 4X missense variants lead to significant functional inactivation.	NLGN3 NLGN4X	2.21e-05	2	164	2	28948087
Pubmed	Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5.	DUSP10 DMD	2.21e-05	2	164	2	23543058
Pubmed	High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.	PGR MKI67	2.21e-05	2	164	2	25600243
Pubmed	Myocyte enhancer factor 2 (MEF2) tethering to muscle selective A-kinase anchoring protein (mAKAP) is necessary for myogenic differentiation.	AKAP6 MEF2A	2.21e-05	2	164	2	22484155
Pubmed	Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism.	NLGN3 NLGN4X	2.21e-05	2	164	2	16648374
Pubmed	A substitution involving the NLGN4 gene associated with autistic behavior in the Greek population.	NLGN3 NLGN4X	2.21e-05	2	164	2	19645625
Pubmed	Expression of prostate apoptosis response (Par-4) is associated with progesterone receptor in breast cancer.	PGR PAWR	2.21e-05	2	164	2	20082875
Pubmed	Mutation screening of X-chromosomal neuroligin genes: no mutations in 196 autism probands.	NLGN3 NLGN4X	2.21e-05	2	164	2	15274046
Pubmed	Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis.	MEF2C TAL1	2.21e-05	2	164	2	19211936
Pubmed	Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins.	MEF2A MEF2C	2.21e-05	2	164	2	21741404
Pubmed	Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.	MECP2 PGR	2.21e-05	2	164	2	24531693
Pubmed	Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma.	MEF2A MEF2C	2.21e-05	2	164	2	17611778
Pubmed	No evidence for involvement of genetic variants in the X-linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level.	NLGN3 NLGN4X	2.21e-05	2	164	2	18189281
Pubmed	Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation.	IFITM5 GLI2	2.21e-05	2	164	2	23530031
Pubmed	Disorder-associated mutations lead to functional inactivation of neuroligins.	NLGN3 NLGN4X	2.21e-05	2	164	2	15150161
Pubmed	Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients.	NLGN3 NLGN4X	2.21e-05	2	164	2	15622415
Pubmed	Absence of glial α-dystrobrevin causes abnormalities of the blood-brain barrier and progressive brain edema.	DTNA DMD	2.21e-05	2	164	2	23043099
Pubmed	Analysis of the genes encoding neuroligins NLGN3 and NLGN4 in Bulgarian patients with autism.	NLGN3 NLGN4X	2.21e-05	2	164	2	23431752
Pubmed	SNX17 Mediates Dendritic Spine Maturation via p140Cap.	SNX17 SRCIN1	2.21e-05	2	164	2	37704928
Pubmed	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis.	CDCA3 KIF18B	2.21e-05	2	164	2	25236463
Pubmed	Absence of coding mutations in the X-linked genes neuroligin 3 and neuroligin 4 in individuals with autism from the IMGSAC collection.	NLGN3 NLGN4X	2.21e-05	2	164	2	16508939
Pubmed	NLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec population.	NLGN3 NLGN4X	2.21e-05	2	164	2	15389766
Pubmed	Functional cloning of SPIN-2, a nuclear anti-apoptotic protein with roles in cell cycle progression.	SPIN2A SPIN2B	2.21e-05	2	164	2	12145692
Pubmed	Distinct cytoplasmic domains in Plexin-A4 mediate diverse responses to semaphorin 3A in developing mammalian neurons.	PLXNA3 PLXNA4	2.21e-05	2	164	2	24619647
Pubmed	Nuclear receptor coactivator-6 attenuates uterine estrogen sensitivity to permit embryo implantation.	NCOA6 PGR	2.21e-05	2	164	2	23079602
Pubmed	Variations analysis of NLGN3 and NLGN4X gene in Chinese autism patients.	NLGN3 NLGN4X	2.21e-05	2	164	2	24570023
Pubmed	KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.	KAT6A YY1AP1	2.21e-05	2	164	2	34808502
Pubmed	Decreased Srcasm expression in hyperproliferative cutaneous lesions.	TOM1L1 MKI67	2.21e-05	2	164	2	19220627
Pubmed	Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers.	LILRB3 LILRB1	2.21e-05	2	164	2	20631139
Pubmed	Mutation screening in the Greek population and evaluation of NLGN3 and NLGN4X genes causal factors for autism.	NLGN3 NLGN4X	2.21e-05	2	164	2	23851596
Pubmed	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.	TPR MAP1B YTHDC2 NUP210 MKI67 NUP160 NXF1 SON	2.65e-05	250	164	8	33536335
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	EXOSC10 BCLAF1 KNSTRN CHD7 SPECC1L ANKHD1 MECP2 SHC3 SPIN1 PCSK6 MKI67 ANKRD17 CEP131 PAWR GOLGA2 NXF1 DNMT1 ATP5F1B SON	2.73e-05	1371	164	19	36244648
Pubmed	Plexin signaling via off-track and rho family GTPases.	PLXNA3 PLXNA4 PLXNA2	2.84e-05	13	164	3	11604131
Pubmed	Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation.	PLXNA3 PLXNA4 PLXNA2	2.84e-05	13	164	3	22723296
Pubmed	Functional assembly of accessory optic system circuitry critical for compensatory eye movements.	PLXNA3 PLXNA4 PLXNA2	2.84e-05	13	164	3	25959730
Interaction	RCOR1 interactions	TPR TBC1D15 CHD7 GIT2 ANKHD1 NCKAP5L MECP2 ZNF516 MKI67 ZBTB5 ANKRD17 CEP131 TADA2A TAL1 GOLGA2 NXF1	2.50e-06	494	162	16	int:RCOR1
Interaction	SEMA5A interactions	PLXNA3 PLXNA4 PLXNA2	1.74e-05	7	162	3	int:SEMA5A
Interaction	HRAS interactions	CDCA3 TRAF7 TPR EPS8 ANKS6 SNX17 KIAA1549 MCL1 CBL FANCD2 HOXB5 SLC9A1 EHBP1L1 IGF2R ARVCF NECTIN2 KNDC1 PLXNA2	2.25e-05	725	162	18	int:HRAS
Interaction	CCDC86 interactions	MAP1B ARHGAP23 ARHGEF5 KAT6A SH3BP1 MECP2 FANCD2 MKI67	3.08e-05	151	162	8	int:CCDC86
Interaction	SEMA6D interactions	PLXNA3 FANCD2 PLXNA4 PLXNA2	3.16e-05	23	162	4	int:SEMA6D
Interaction	CDKL5 interactions	MECP2 KCNB1 PLPPR4 AJM1 MACF1 CEP131 LRRC7	3.60e-05	113	162	7	int:CDKL5
Interaction	CDH1 interactions	CDCA3 PAG1 ARHGAP23 SRCIN1 PLEKHA6 CBL FANCD2 SLC9A1 EHBP1L1 IGF2R ARVCF KIAA1217 NECTIN2 MKI67 MACF1 LRRC7 JPT2 GOLGA2	4.78e-05	768	162	18	int:CDH1
Interaction	KCTD13 interactions	TOM1L2 EPS8 CARMIL2 MAP1B ARHGAP23 BCLAF1 KIAA1549 YTHDC2 SRCIN1 SPECC1L PLEKHA6 PPFIA3 OGDH MECP2 NLGN3 PLPPR4 ARVCF AJM1 KIAA1217 PLXNA4 KNDC1 MACF1 LRRC7 DMD CORO7 ATP5F1B	4.86e-05	1394	162	26	int:KCTD13
Interaction	ATG16L1 interactions	CDCA3 TRAF7 PSMC2 YTHDC2 GIT2 SPECC1L NCKAP5L IGF2R GLI2 KIAA1217 HPS4 NUP210 NECTIN2 SORBS3 CEP131 LRRC7 CORO7 NUP160 GOLGA2 NXF1 PLXNA2 DNMT1 ATP5F1B	5.65e-05	1161	162	23	int:ATG16L1
Interaction	MAGOH interactions	MAP1B MECP2 FANCD2 RBM22 SPIN1 SPIN2A TADA2A GOLGA2 NXF1 SON	5.67e-05	264	162	10	int:MAGOH
Interaction	XRCC6 interactions	TPR EPS8 NCOA6 EXOSC10 MAP1B BCLAF1 MCL1 YTHDC2 CHD7 CBL MECP2 PGR FANCD2 MKI67 FGD5 TAL1 JPT2 NXF1 DNMT1 ATP5F1B	5.75e-05	928	162	20	int:XRCC6
Interaction	OR13A1 interactions	CLTCL1 OR13A1	6.42e-05	2	162	2	int:OR13A1
Interaction	OIP5 interactions	TRAF7 EPS8 KNSTRN GIT2 NCKAP5L HOXB5 CBY2 SORBS3 GPANK1	6.71e-05	217	162	9	int:OIP5
Interaction	CGGBP1 interactions	KAT6A MECP2 SPIN1 MKI67 SPIN2B	7.26e-05	54	162	5	int:CGGBP1
Interaction	MEF2B interactions	UBN2 MEF2A MEF2C	8.02e-05	11	162	3	int:MEF2B
Interaction	HDAC1 interactions	TPR TBC1D15 UBQLN4 PSMC2 ANKHD1 TTC4 MECP2 MEF2A CASZ1 FANCD2 CIITA GLI2 CHD5 ZNF516 MKI67 ZBTB5 ANKRD17 CEP131 TADA2A TAL1 NXF1 DNMT1	8.05e-05	1108	162	22	int:HDAC1
Interaction	LCK interactions	CDCA3 PAG1 DTNA TRIM35 KIAA1549 PLEKHA6 CBL TTC4 NCKAP5L FANCD2 KIAA1217 MACF1 GOLGA2	9.77e-05	463	162	13	int:LCK
Interaction	OTUD7A interactions	KCNB1 PLPPR4 KNDC1 MACF1 LRRC7	1.03e-04	58	162	5	int:OTUD7A
Interaction	MAPRE3 interactions	KNSTRN SPECC1L CBL NCKAP5L KIAA1217 MACF1 CEP131 KIF18B GOLGA2	1.05e-04	230	162	9	int:MAPRE3
Interaction	NRXN2 interactions	MECP2 NLGN3 MACF1	1.06e-04	12	162	3	int:NRXN2
Interaction	SIRT7 interactions	TPR EXOSC10 EPPK1 MAP1B PSMC2 YTHDC2 CHD7 ANKHD1 IGF2R NUP210 MKI67 ANKRD17 MACF1 NUP160 NXF1 DNMT1 SON	1.07e-04	744	162	17	int:SIRT7
Interaction	RAC1 interactions	CDCA3 TRAF7 EPS8 CARMIL2 ARHGAP23 DTNA SH3BP1 PSMC2 KIAA1549 GIT2 NCKAP5L FANCD2 SLC9A1 EHBP1L1 IGF2R PARD6A HPS4 NECTIN2 MACF1 FGD5 NUP160	1.27e-04	1063	162	21	int:RAC1
Cytoband	Xp11.1	SPIN2A SPIN2B	7.57e-05	4	164	2	Xp11.1
GeneFamily	Tudor domain containing\|Spindlin family	SPIN1 SPIN2A SPIN2B	2.00e-06	5	107	3	1089
GeneFamily	Plexins	PLXNA3 PLXNA4 PLXNA2	1.65e-05	9	107	3	683
GeneFamily	Myocyte enhancer factor 2 proteins\|MADS box family	MEF2A MEF2C	2.07e-04	4	107	2	649
GeneFamily	Myocyte enhancer factor 2 proteins\|MADS box family	MEF2A MEF2C	3.43e-04	5	107	2	1086
GeneFamily	CD molecules\|Inhibitory leukocyte immunoglobulin like receptors	LILRB3 LILRB1	3.43e-04	5	107	2	1182
GeneFamily	Nucleoporins	TPR NUP210 NUP160	8.82e-04	32	107	3	1051
GeneFamily	EF-hand domain containing\|Plakins	EPPK1 MACF1	9.49e-04	8	107	2	939
GeneFamily	Tudor domain containing	SPIN1 SPIN2A SPIN2B	1.35e-03	37	107	3	780
GeneFamily	Zinc fingers CXXC-type	TET3 DNMT1	2.20e-03	12	107	2	136
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	MAP1B PPP1R3C SLC9A1 MKI67 PPP1R3F	4.44e-03	181	107	5	694
GeneFamily	DNA helicases	RTEL1 CHD7	4.45e-03	17	107	2	1167
GeneFamily	WD repeat domain containing\|DDB1 and CUL4 associated factors	AMBRA1 BRWD1	4.99e-03	18	107	2	498
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	DTNA DMD	4.99e-03	18	107	2	91
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	AKAP6 PLXNA3 MAP1B ARHGAP23 KIAA1549 SRCIN1 PLEKHA6 NEB UBN2 CASZ1 NLGN4X KIAA1549L CLCN4 PLPPR4 CHD5 PLXNA4 LRRC7 FRMPD3 KLHL14 TAL1 CCDC17 BRWD1	1.35e-06	1106	162	22	M39071
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HDA	PLXNA3 MAP1B ARHGAP23 SRCIN1 PLEKHA6 NEB CASZ1 NLGN4X CLCN4 PLPPR4 CHD5 PLXNA4 LRRC7 KLHL14	3.40e-06	506	162	14	M39067
Coexpression	LAKE_ADULT_KIDNEY_C27_VASCULAR_SMOOTH_MUSCLE_CELLS_AND_PERICYTES	AKAP6 EPS8 MYLK MEF2C SLIT3 PAWR DMD SDK1	5.71e-06	155	162	8	M39246
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRCIN1 PPFIA3 MEF2C KIAA1549L KCNB1 PLPPR4 PTPRN CHD5 PLXNA4 UNC80 SEZ6	1.58e-10	193	164	11	be28070c049e7cb68bcd54f582226eb2f5e4bc1c
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRCIN1 PPFIA3 MEF2C KIAA1549L KCNB1 PLPPR4 PTPRN CHD5 PLXNA4 UNC80 SEZ6	1.58e-10	193	164	11	0c652ebe22ce5d2927599dd97ef1920547858395
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRCIN1 PPFIA3 MEF2C KIAA1549L KCNB1 PLPPR4 PTPRN CHD5 PLXNA4 UNC80 SEZ6	1.58e-10	193	164	11	8689a70a33a7c3823dc647d41ac0160e7c3ae396
ToppCell	PBMC-Severe-cDC_11\|Severe / Compartment, Disease Groups and Clusters	CLTCL1 CARMIL2 MYLK TOP6BL PLEKHA6 SEMA4G CLCN4 PAWR DMD MTSS2	1.26e-09	178	164	10	0667abc05eb2254710b9c648c65b7cfdfe7831b7
ToppCell	Bronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	AKAP6 CLTCL1 MYLK DTNA PGR PPP1R3C NLGN3 HECTD2 PLXNA4	8.12e-09	159	164	9	7cda111bb98f1241989e49d490bdf51a712ea589
ToppCell	RA-13._Vascular_Smooth_Muscle\|RA / Chamber and Cluster_Paper	AKAP6 MYLK DTNA MEF2C HMCN2 SLIT3 PAWR DMD SDK1	2.75e-08	183	164	9	818fd886e0188091310825f9145fa53328f2c979
ToppCell	LA-13._Vascular_Smooth_Muscle\|LA / Chamber and Cluster_Paper	AKAP6 MYLK DTNA HMCN2 SLIT3 MACF1 PAWR DMD SDK1	3.47e-08	188	164	9	34e1b074a3995aa46ab194eb45115d76d1a5514d
ToppCell	LA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	AKAP6 MYLK DTNA HMCN2 SLIT3 MACF1 PAWR DMD SDK1	3.64e-08	189	164	9	6b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK MAP1B DTNA PGR HMCN2 GLI2 SLIT3 LRRC7 DMD	4.97e-08	196	164	9	1522958a92e0126326a9f0d9fb1c5b5c50b001ea
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK MAP1B DTNA PGR HMCN2 GLI2 SLIT3 LRRC7 DMD	4.97e-08	196	164	9	1c8294014713684b50885e638668f2ce75f357f0
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Pericyte\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	AKAP6 EPS8 MYLK MAP1B MEF2C PPP1R3C FHAD1 DMD ATP1A4	5.91e-08	200	164	9	b22cae282591d8dead9869c2adbb9632615f50f7
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell\|Adult / Lineage, Cell type, age group and donor	AKAP6 MYLK MAP1B DTNA PLPPR4 SLIT3 SORBS3 DMD	2.55e-07	172	164	8	c62cad0f4212d1e9ea1ec3143ad3c4e06aff0ebf
ToppCell	COVID-mDC1-\|COVID / Condition, Cell_class and T cell subcluster	AKAP6 MYLK CARD10 PLEKHA6 SPTBN5 CLCN4 BRWD1-AS2 PAWR	2.91e-07	175	164	8	83a95d6fc2ddf3ec53f05825bbc982fb8d2ccd15
ToppCell	COVID-mDC1\|COVID / Condition, Cell_class and T cell subcluster	AKAP6 MYLK CARD10 PLEKHA6 SPTBN5 CLCN4 BRWD1-AS2 PAWR	2.91e-07	175	164	8	b9280444016e21c28131a61df65cc5c56d402412
ToppCell	PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_G2M\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 KNSTRN FANCD2 NLGN3 KIAA1549L HECTD2 MKI67 KIF18B	3.17e-07	177	164	8	3e149bff1f1b393a7abe98984e37981c8296f95d
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 MYLK MAP1B PGR GLI2 SLIT3 SORBS3 DMD	4.08e-07	183	164	8	667717366cb181b8a04a347e64f0f5a4dfc6ee7f
ToppCell	RA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	AKAP6 MYLK DTNA HMCN2 SLIT3 PAWR DMD SDK1	4.08e-07	183	164	8	cae2ee08f985a6f005b4b8e959e465350315156a
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	AKAP6 MAP1B DTNA MEF2C PPP1R3C SLIT3 DMD SDK1	4.62e-07	186	164	8	4780af76237d7af2abbe2d8d5530cdf53e3ed0b7
ToppCell	COVID-19-Fibroblasts-Airway_smooth_muscle\|COVID-19 / group, cell type (main and fine annotations)	AKAP6 MYLK MAP1B DTNA SLIT3 PLXNA4 DMD SDK1	4.81e-07	187	164	8	464a0c3b92b778911b5f9cd73642e09e3472063a
ToppCell	facs-Pancreas-Endocrine-24m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1B UBN2 KCNB1 PTPRN CHD5 ZNF516 UNC80 SON	5.01e-07	188	164	8	a91443aa8fa8fa87f7501c59219daa0305bd0bbf
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B MEF2C KCNB1 CHD5 SLIT3 DMD SDK1	5.22e-07	189	164	8	7fbe855bfdb47d35e040b04a80fe4b729a3764e8
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B MEF2C KCNB1 CHD5 SLIT3 DMD SDK1	5.22e-07	189	164	8	06b35abecd29f902cf251fcc1f6ad33db7ab08a2
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B MEF2C EHBP1L1 GLI2 SLIT3 DMD SDK1	5.22e-07	189	164	8	127ad2ba3e794df8cce2eee3e4171bccb5aad51b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B MEF2C EHBP1L1 GLI2 SLIT3 DMD SDK1	5.22e-07	189	164	8	2cfb4d12f75678d1619f4743838a0e954bd57761
ToppCell	Hippocampus-Neuronal\|Hippocampus / BrainAtlas - Mouse McCarroll V32	PDE4A MAP1B SH3BP1 PPFIA3 PGR PTPRN CHD5 UNC80	6.36e-07	194	164	8	8aeb347b3024354c9505f4f0fddf0b843489dc6b
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAP1B MEF2C KIAA1549L KCNB1 PLPPR4 CHD5 LRRC7 UNC80	6.87e-07	196	164	8	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	Bronchial-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	AKAP6 MYLK MAP1B DTNA PGR HMCN2 SLIT3 DMD	7.14e-07	197	164	8	bf0520a94ebb1d2f94de9f526d17e0b0e8fe7052
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAP1B MEF2C KIAA1549L KCNB1 PLPPR4 CHD5 LRRC7 UNC80	7.41e-07	198	164	8	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW23-Neuronal-Cortical_neuron\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	PLXNA3 EXOSC10 MAP1B KIAA1549L PTPRN PLXNA4 LRRC7 SEZ6	8.00e-07	200	164	8	7bba2ff09349c8db3d1ccf53520b12cbf7b0abac
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B MEF2C PPP1R3C SLIT3 DMD ATP1A4	8.00e-07	200	164	8	a3a1e35934d676c39f917652e50c502cb2f613c1
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	MAP1B MEF2C KIAA1549L KCNB1 PLPPR4 CHD5 LRRC7 UNC80	8.00e-07	200	164	8	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	LPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B PERM1 MEF2C PPP1R3C DMD ATP1A4	8.00e-07	200	164	8	c06426f877919bdd267ea2fd7e7973c6619832ae
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Pericyte-Pericyte_2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	EPS8 PAG1 MYLK MAP1B PERM1 MEF2C PPP1R3C FHAD1	8.00e-07	200	164	8	786f1ae53e60b5ffbf4bfd393d10b802478148b3
ToppCell	TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Conventional_Leiomyosarcoma\|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9	AKAP6 MYLK DTNA CASZ1 C12orf54 PAWR DMD	1.63e-06	153	164	7	ec6fe6b8c884fa76adc7a0f9db041f7b1567a2ee
ToppCell	RV-13._Vascular_Smooth_Muscle\|RV / Chamber and Cluster_Paper	EPPK1 MYLK MAP1B HMCN2 SLIT3 PAWR DMD	2.29e-06	161	164	7	47b3b7662cbb671ccc086dc0a0cabd65f63eb5a1
ToppCell	TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Classical-8\|TCGA-Thryoid / Sample_Type by Project: Shred V9	EPS8 ARHGAP23 SLIT3 DMD TET3 SDK1 NXF1	3.04e-06	168	164	7	00646601548b0fee42ae16bfa5e93603bc7c5129
ToppCell	3'_v3-Lung-Myeloid_Mac-Intestinal_macrophages\|Lung / Manually curated celltypes from each tissue	AKAP6 EPS8 DTNA NCKAP5L MEF2C PPP1R3C CIITA	3.16e-06	169	164	7	241644823e6f949aaf4c671d4579721d7ef6b0e5
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-Myofibro_2\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	PAG1 CASZ1 KIAA1549L PLPPR4 PLXNA4 LRRC7 GPANK1	3.28e-06	170	164	7	fefb07a7e308b620f946b9ff2b01e1796446fe38
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 KCNB1 GLI2 CHD5 SLIT3 DMD SDK1	3.98e-06	175	164	7	d52794426f2703a80e91ae0a8ff2d8e0ce4aa4a8
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 KCNB1 GLI2 CHD5 SLIT3 DMD SDK1	3.98e-06	175	164	7	454f03e6109d65f5db08dbb41ecc19ffb6bbc4e0
ToppCell	PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 PAG1 KNSTRN PERM1 IGF2R MKI67 SEZ6	4.28e-06	177	164	7	2b63f0529ef73e0eede9b7ef1f08b0a0426a9c82
ToppCell	PBMC-Mild-cDC_11\|Mild / Compartment, Disease Groups and Clusters	CARMIL2 MYLK TOM1L1 CLCN4 PAWR DMD SDK1	4.28e-06	177	164	7	974305e4c0eff90134c4e58cf11b955d1eee0501
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C SLIT3 SORBS3 DMD	4.28e-06	177	164	7	a8625d14682183cf77cb51eaf11bc15a3528f586
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C SLIT3 SORBS3 DMD	4.28e-06	177	164	7	3645e2f4a48283f290f85c49c3e79e3f58ac9aa6
ToppCell	Control-Fibroblasts-Airway_smooth_muscle\|Control / group, cell type (main and fine annotations)	AKAP6 MYLK MAP1B DTNA PPP1R3C SLIT3 DMD	4.78e-06	180	164	7	d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-myocytic-myofibroblast_(RSPO2+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MYLK MAP1B DTNA PPP1R3C NLGN4X LRRC7 DMD	5.33e-06	183	164	7	61a73de857f4ae02dcba3af348f436f602b28ff2
ToppCell	343B-Lymphocytic-CD4_T-cell-Proliferating_T_cell\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	CDCA3 KNSTRN CIITA LRRC27 MKI67 KIF18B TAL1	5.33e-06	183	164	7	f03d87b556a3d50360d4eb6126b3466fe7266677
ToppCell	Mild/Remission-B_intermediate-10\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	LRRK1 NEB LILRB1 MEF2A PCSK6 PPP1R3F MACF1	5.33e-06	183	164	7	278064c9f0582463b83bf156d34e77f60187613b
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 MAP1B MEF2C GLI2 SLIT3 SORBS3 DMD	5.73e-06	185	164	7	7092436b4db90289516ed130ade596e3021cffaf
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 MAP1B MEF2C GLI2 SLIT3 SORBS3 DMD	5.73e-06	185	164	7	a8ca7819066d5297ef6966e7f3e2c9f8a7673fdc
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	AKAP6 MAP1B DTNA MEF2C PPP1R3C SLIT3 DMD	5.93e-06	186	164	7	a95744b8649096bd7cfc3591a02841fa411085b3
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C GLI2 SLIT3 DMD	6.15e-06	187	164	7	ec4b694487cc446999c7b27b119950a4f252c4b3
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C GLI2 SLIT3 DMD	6.15e-06	187	164	7	530e4e6d91b5c0d9aa4543caa2b734a1674c5788
ToppCell	LA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	AKAP6 CLTCL1 DTNA NEB CASZ1 LRRC7 DMD	6.36e-06	188	164	7	6d249fe92d51a19da19ec14bb2262d394255d577
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	PAG1 MYLK CASZ1 PLPPR4 PLXNA4 LRRC7 PLXNA2	6.36e-06	188	164	7	3004e961d214919e08c7cd5f10c3de5cf85b35a3
ToppCell	Fetal_29-31_weeks-Immune-monocyte-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	LILRB3 PDE4A LILRB1 MEF2C EHBP1L1 CIITA IL17RA	6.82e-06	190	164	7	ad297172a74a80ed5c10f921e15efd1da0fd2d6b
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C SLIT3 SORBS3 DMD	6.82e-06	190	164	7	5681c211baeed4af82a2bbc13420f6a7b487581c
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	PAG1 CASZ1 FANCD2 PLPPR4 LRRC7 KIF18B PLXNA2	6.82e-06	190	164	7	e83fa8b711aa79a1767818474f1c193b674b1c31
ToppCell	Adult-Immune-monocyte-D175\|Adult / Lineage, Cell type, age group and donor	PAG1 LILRB3 LRRK1 LILRB1 MEF2C EHBP1L1 IL17RA	7.06e-06	191	164	7	cbebb4d9550fdcd606cb3685ac9546c6b73fd422
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C GLI2 SLIT3 DMD	7.06e-06	191	164	7	7b0d42a877540dbb346a76a62403e0d5d3e07fa6
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MAP1B MEF2C GLI2 SLIT3 DMD	7.06e-06	191	164	7	cd854b9c426924fdc84bf7f411f6dea447143e79
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 PAG1 MYLK MAP1B GLI2 SLIT3 DMD	7.30e-06	192	164	7	24e2f15f5767a97eb3b389922bcfd7b13805e1ce
ToppCell	droplet-Liver-LIVER_HEP-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP23 MEF2C KCNB1 FGD5 TAL1 PLXNA2 MTSS2	7.55e-06	193	164	7	d485634c564b268e344b6a2863c26f6adaec9e38
ToppCell	LA\|World / Chamber and Cluster_Paper	EPS8 MAP1B TOP6BL HMCN2 GLI2 PCSK6 SDK1	7.55e-06	193	164	7	d4bf89437216baf489ea0239136dcedf3b6714af
ToppCell	Posterior_cortex-Neuronal\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	CARMIL2 MAP1B SH3BP1 PGR PTPRN CHD5 UNC80	7.55e-06	193	164	7	b4989e3436e84dbec3789b46057e0f7a0ebf09d4
ToppCell	droplet-Limb_Muscle-MUSCLE\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TPR BCLAF1 DBP MEF2A MACF1 TET3 SON	7.81e-06	194	164	7	e3d63874111d1e8da3977329426e4dcf68d6de87
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK DTNA GLI2 SLIT3 PLXNA4 DMD SDK1	7.81e-06	194	164	7	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PAG1 MYLK MAP1B PGR GLI2 KIAA1217 SLIT3	7.81e-06	194	164	7	90efdbd7f1c85fd7fd622b10340250b1d8fc1197
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PAG1 MYLK MAP1B PGR GLI2 KIAA1217 SLIT3	7.81e-06	194	164	7	df82cce5ebeb73740b02cf816c6df82253cfd566
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B DTNA MEF2C SLIT3 DMD SDK1	7.81e-06	194	164	7	5c3b2b05d1e4f146551fe4c920263d8e6ca34de3
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK DTNA GLI2 SLIT3 PLXNA4 LRRC7 SDK1	7.81e-06	194	164	7	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AKAP6 MAP1B DTNA MEF2C SLIT3 DMD SDK1	7.81e-06	194	164	7	ab9cad697f9209d2889bc02b43b502dfeb2ebfef
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	MYLK PPP1R3C PLPPR4 HECTD2 GLI2 SLIT3 MACF1	8.08e-06	195	164	7	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1B KCNB1 PTPRN ZNF516 MACF1 UNC80 SON	8.08e-06	195	164	7	3e519cffa6144a62b06124642a14c9ff39b76554
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1B KCNB1 PTPRN ZNF516 MACF1 UNC80 SON	8.08e-06	195	164	7	7796ea9247f4c63762f0de8490fed08b9717fa23
ToppCell	COVID-19-Myeloid-Monocytes\|COVID-19 / group, cell type (main and fine annotations)	PAG1 LILRB3 CBL LILRB1 CIITA IL17RA TET3	8.35e-06	196	164	7	04d710267658ea5601ae2cfb4ed5acb8a29bd8a1
ToppCell	(5)_Fibroblasts-(5)_Fibroblast-K_(Pericytes)\|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)	AKAP6 EPS8 MYLK MAP1B MEF2C PAWR DMD	8.35e-06	196	164	7	541b1fcf509e362f6f48720046cb5378aaf7c591
ToppCell	facs-Skin-Telogen-3m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EPS8 TRIM35 ARVCF SLIT3 MACF1 DMD PLXNA2	8.35e-06	196	164	7	c936014125b2ed5f796221b74acb77b8f8359875
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	EPS8 MYLK MAP1B PGR GLI2 SLIT3 DMD	8.63e-06	197	164	7	80e153790cef37b743e22a7370ff5b3a6abf147d
ToppCell	Parenchymal-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	AKAP6 MYLK MAP1B DTNA EHBP1L1 SLIT3 DMD	8.92e-06	198	164	7	bd42c03e384e64f61b02618cf1a5440033bb04b2
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAP1B MEF2C KIAA1549L KCNB1 CHD5 LRRC7 UNC80	8.92e-06	198	164	7	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAP1B MEF2C KIAA1549L PLPPR4 CHD5 LRRC7 UNC80	8.92e-06	198	164	7	0ff30edfd3c133a42e8cb96e1631a1143215f808
ToppCell	18-Airway-Mesenchymal-Mesenchyme_RSPO2+\|Airway / Age, Tissue, Lineage and Cell class	CDCA3 MYLK KNSTRN PPP1R3C MKI67 MACF1 KIF18B	9.22e-06	199	164	7	7ac35e8f45dcdc702422dabd8f3e4d03e2bf61af
ToppCell	5'-GW_trimst-2-SmallIntestine-Mesenchymal-Pericytes-angiogenic_pericyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	EPS8 MYLK MAP1B MEF2C PLPPR4 SLIT3 PAWR	9.22e-06	199	164	7	9e32644b93fb1c4946dbe388fd5c357304d14e36
ToppCell	Parenchymal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	AKAP6 MYLK MAP1B DTNA EHBP1L1 SLIT3 DMD	9.22e-06	199	164	7	b1753474152b82a0b811b9878c890a359e14919a
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	MAP1B MEF2C CHD5 PLXNA4 LRRC7 PLXNA2 SEZ6	9.22e-06	199	164	7	77b4aa00f14b86ef5db0490be98787e063979541
ToppCell	Control_saline-Mesenchymal_fibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK SPECC1L PLEKHA6 PPP1R3C PLPPR4 SLIT3 MACF1	9.53e-06	200	164	7	64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe
ToppCell	mild-HLA-DR+_CD83+_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	LILRB3 MCL1 LILRB1 MEF2A CIITA IL17RA TET3	9.53e-06	200	164	7	934c2efc780318c66d667ca75be0de350361d351
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B MEF2C PPP1R3C DMD ATP1A4	9.53e-06	200	164	7	9169a9ec8e9ab95d90a64c5a19ac666a5cf82313
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-GABAergic_neurons\|GW26 / Sample Type, Dataset, Time_group, and Cell type.	MAP1B SRCIN1 UBN2 MEF2C CHD5 KLHL14 SDK1	9.53e-06	200	164	7	bad32a95b759fad509401b07bc96a56687c2a592
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Pericyte\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	EPS8 MYLK MAP1B MEF2C PPP1R3C FHAD1 DMD	9.53e-06	200	164	7	4e1e19214aeebbdca004de7faaf4cc9d18498591
ToppCell	Bronchial-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	AKAP6 MYLK MAP1B DTNA HMCN2 SLIT3 DMD	9.53e-06	200	164	7	a66449b22b39dd6987fc2c3ed160d24564234ced
ToppCell	Sepsis-Bac-SEP-Myeloid-cDC1\|Bac-SEP / Disease, condition lineage and cell class	AKAP6 ANKS6 MYLK LPIN3 CIITA PAWR DMD	9.53e-06	200	164	7	cd381644fd8b8674a017d267bfbb00f2668294ae
ToppCell	LPS_only-Mesenchymal_myocytic-Pericyte\|LPS_only / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B MEF2C PPP1R3C DMD ATP1A4	9.53e-06	200	164	7	8c8ef2b19ab5b1bfc0fae6c38a330f464f28e86f
ToppCell	LPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B HECTD2 PLXNA4 DMD ATP1A4	9.53e-06	200	164	7	dcdaec3ca3a3024dc1b8788c417003f84c2bffdc
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK SPECC1L PLEKHA6 PPP1R3C PLPPR4 SLIT3 MACF1	9.53e-06	200	164	7	a1fc74c1b27e104895910bc7cdce7ba33d30df7e
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_3\|Control_saline / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MEF2C PPP1R3C SLIT3 DMD ATP1A4	9.53e-06	200	164	7	b0866b497aa71d06cef25f9a335fa584e95fa7e0
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK SPECC1L PLEKHA6 PPP1R3C PLPPR4 SLIT3 MACF1	9.53e-06	200	164	7	bd8cf33502adea320e91ca2af14e1911d88ad374
ToppCell	LPS_only-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_only / Treatment groups by lineage, cell group, cell type	AKAP6 MYLK MAP1B MEF2C PPP1R3C DMD ATP1A4	9.53e-06	200	164	7	7c62678cf408aaaf98d6df0fb27814d2007c4521
ToppCell	390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	ARHGAP23 DTNA CASZ1 C12orf54 BRWD1-AS2 CCDC17	1.70e-05	146	164	6	cffa91d76606f74553d81150adbb23b003746316
Drug	Fluticasone propionate [80474-14-2]; Up 200; 8uM; MCF7; HT_HG-U133A	MAP1B PRSS16 DTNA YTHDC2 PPFIA3 EHBP1L1 CLCN4 ARVCF PARD6A PCSK6 GOLGA2	1.72e-07	199	160	11	7348_UP
Drug	Carisoprodol [78-44-4]; Down 200; 15.4uM; HL60; HT_HG-U133A	DTNA MCL1 LRRK1 CBL LILRB1 SLC9A1 MACF1 TADA2A NUP160 GOLGA2	1.38e-06	197	160	10	1314_DN
Drug	Mesalamine [89-57-6]; Down 200; 26.2uM; PC3; HT_HG-U133A	MYLK MAP1B AMBRA1 PPFIA3 HOXB5 PARD6A NUP210 HERC3 NUP160 GOLGA2	1.52e-06	199	160	10	5888_DN
Drug	Securinine [5610-40-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A	DTNA TOP6BL DBP PPFIA3 CASZ1 SLC9A1 PARD6A SORBS3 DUSP10	1.02e-05	195	160	9	3470_DN
Drug	Diphenidol hydrochloride [3254-89-5]; Down 200; 11.6uM; HL60; HT_HG-U133A	RTEL1 MCL1 LRRK1 MECP2 SPIN1 SORBS3 MACF1 TADA2A BRWD1	1.06e-05	196	160	9	2374_DN
Drug	Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; PC3; HT_HG-U133A	MYLK RTEL1 MCL1 LRRK1 PPP1R3C CLCN4 GLI2 PLXNA2 MTSS2	1.06e-05	196	160	9	7129_UP
Drug	Glipizide [29094-61-9]; Down 200; 9uM; MCF7; HT_HG-U133A	MAP1B RTEL1 DTNA YTHDC2 GIT2 ARVCF SORBS3 PAWR TADA2A	1.11e-05	197	160	9	1508_DN
Drug	Moxonidine [75438-57-2]; Up 200; 16.6uM; MCF7; HT_HG-U133A	RTEL1 DTNA GIT2 CBL SLC9A1 ARVCF HPS4 ZNF516 GOLGA2	1.11e-05	197	160	9	7343_UP
Drug	Dropropizine (R,S) [17692-31-8]; Down 200; 17uM; PC3; HT_HG-U133A	EPPK1 YTHDC2 TOP6BL LRRK1 MECP2 MEF2C CLCN4 NUP210 HERC3	1.11e-05	197	160	9	5106_DN
Drug	Cefadroxil [50370-12-2]; Down 200; 11uM; PC3; HT_HG-U133A	MAP1B AMBRA1 SEMA4G KIAA1549L PLPPR4 SORBS3 HERC3 GOLGA2 MTSS2	1.15e-05	198	160	9	4080_DN
Drug	Bemegride [64-65-3]; Up 200; 25.8uM; HL60; HT_HG-U133A	RTEL1 SH3BP1 YTHDC2 CASZ1 SEMA4G SPTBN5 CHD5 DMD ATP4A	1.15e-05	198	160	9	3051_UP
Drug	Cinnarizine [298-57-7]; Down 200; 10.8uM; PC3; HT_HG-U133A	MAP1B MCL1 MEF2C CASZ1 PPP1R3C HOXB5 HPS4 SORBS3 BRWD1	1.20e-05	199	160	9	5817_DN
Drug	chrysene	PDE4A MYLK ARHGAP23 BCLAF1 TRIM35 SH3BP1 SRCIN1 LRRK1 DBP PPFIA3 NEB MEF2C CASZ1 FHAD1 HMCN2 SPIN1 MKI67 TADA2A NXF1	1.23e-05	871	160	19	ctd:C031180
Drug	cytochalasin B; Up 200; 20.8uM; MCF7; HT_HG-U133A_EA	EPPK1 DTNA MCL1 GIT2 MECP2 PCSK6 NUP210 PAWR	3.16e-05	173	160	8	1122_UP
Drug	5224221; Up 200; 12uM; MCF7; HT_HG-U133A_EA	MAP1B PRSS16 DTNA GIT2 PLEKHA6 PPFIA3 CASZ1 DUSP10	4.03e-05	179	160	8	839_UP
Drug	polyproline	TPR EPS8 TOM1L1 SH3BP1 CBL PGR NUP210 SORBS3 YY1AP1 GOLGA2	4.71e-05	295	160	10	CID000439587
Drug	lithium indium	SPIN2A SPIN2B	4.91e-05	2	160	2	CID011116062
Drug	scandium phosphate	SPIN2A SPIN2B	4.91e-05	2	160	2	CID006365269
Drug	rubidium nitrate	SPIN2A SPIN2B	4.91e-05	2	160	2	CID000025731
Drug	Imipenem [74431-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A	MAP1B RTEL1 DTNA MCL1 PLEKHA6 SORBS3 DUSP10 YIPF3	6.61e-05	192	160	8	2873_DN
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; PC3; HT_HG-U133A	TPR MAP1B KAT6A CHD7 MEF2C SPIN1 HPS4 NUP160	6.61e-05	192	160	8	4311_DN
Drug	Triprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A	TPR EPPK1 AMBRA1 GIT2 MECP2 CASZ1 PPP1R3C SLC9A1	6.86e-05	193	160	8	7008_DN
Drug	Carcinine [56897-53-1]; Down 200; 22uM; PC3; HT_HG-U133A	PLXNA3 RTEL1 DBP SEMA4G EHBP1L1 NUP210 SORBS3 MTSS2	6.86e-05	193	160	8	4225_DN
Drug	PHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A	MYLK MAP1B YTHDC2 GIT2 HOXB5 CLCN4 HPS4 IL17RA	7.11e-05	194	160	8	7086_UP
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	NEB MECP2 PGR EHBP1L1 PCSK6 ZNF516 MACF1 HERC3	7.11e-05	194	160	8	5641_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; PC3; HT_HG-U133A	DBP OGDH HOXB5 KIAA1549L NUP210 NECTIN2 SORBS3 IL17RA	7.11e-05	194	160	8	4284_DN
Drug	Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A	DTNA KAT6A NEB CBL MECP2 PPP1R3C SLC9A1 HPS4	7.37e-05	195	160	8	5388_DN
Drug	Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A	PLEKHA6 PPFIA3 SLC9A1 NUP210 NECTIN2 HERC3 DUSP10 BRWD1	7.37e-05	195	160	8	7400_DN
Drug	Bezafibrate [41859-67-0]; Down 200; 11uM; PC3; HT_HG-U133A	GIT2 NEB MECP2 HOXB5 HPS4 HERC3 TADA2A PLXNA2	7.64e-05	196	160	8	6653_DN
Drug	CP-645525-01 [287190-82-3]; Down 200; 10uM; PC3; HT_HG-U133A	AMBRA1 YTHDC2 CHD7 CBL KIAA1549L GLI2 HERC3 NUP160	7.64e-05	196	160	8	7527_DN
Drug	Oxolinic acid [14698-29-4]; Down 200; 15.4uM; PC3; HT_HG-U133A	PLXNA3 RTEL1 MECP2 PPP1R3C KIAA1549L PARD6A IL17RA PLXNA2	7.64e-05	196	160	8	2103_DN
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; PC3; HT_HG-U133A	MAP1B AMBRA1 GIT2 MECP2 SEMA4G HOXB5 SORBS3 DUSP10	7.64e-05	196	160	8	5765_DN
Drug	Cotinine (-) [486-56-6]; Down 200; 22.6uM; MCF7; HT_HG-U133A	MAP1B DTNA YTHDC2 GIT2 PPFIA3 PARD6A SORBS3 TADA2A	7.64e-05	196	160	8	1511_DN
Drug	Coralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A	DBP NEB CBL PGR PPP1R3C PAWR HERC3 IL17RA	7.64e-05	196	160	8	5418_DN
Drug	Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; PC3; HT_HG-U133A	DTNA GIT2 LRRK1 CASZ1 HOXB5 HERC3 NUP160 GOLGA2	7.64e-05	196	160	8	2101_UP
Drug	Cyclopentolate hydrochloride [5870-29-1]; Down 200; 12.2uM; PC3; HT_HG-U133A	MYLK MAP1B AMBRA1 YTHDC2 GIT2 SEMA4G HOXB5 DUSP10	7.64e-05	196	160	8	5734_DN
Drug	Dehydroisoandosterone 3-acetate [853-23-6]; Down 200; 12.2uM; PC3; HT_HG-U133A	MAP1B CBL SEMA4G HOXB5 NUP210 IL17RA TADA2A MTSS2	7.64e-05	196	160	8	6673_DN
Drug	Mebeverine hydrochloride [2753-45-9]; Down 200; 8.6uM; PC3; HT_HG-U133A	MYLK MCL1 CLCN4 PARD6A NUP210 SORBS3 IL17RA TADA2A	7.64e-05	196	160	8	7147_DN
Drug	2-Chloropyrazine [14508-49-7]; Down 200; 35uM; MCF7; HT_HG-U133A	PDE4A MAP1B YTHDC2 SLC9A1 NUP210 DUSP10 TADA2A GOLGA2	7.64e-05	196	160	8	6227_DN
Drug	Norgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; HL60; HT_HG-U133A	AMBRA1 YTHDC2 CBL MECP2 MKI67 MACF1 GOLGA2 BRWD1	7.92e-05	197	160	8	2547_DN
Drug	Vitamin K2 [11032-49-8]; Down 200; 9uM; PC3; HT_HG-U133A	DTNA KAT6A YTHDC2 GIT2 LRRK1 NEB PARD6A SORBS3	7.92e-05	197	160	8	3798_DN
Drug	resveratrol; Down 200; 50uM; PC3; HG-U133A	CDCA3 DTNA CARD10 KIAA1549L ARVCF GLI2 MKI67 IL17RA	7.92e-05	197	160	8	662_DN
Drug	Niridazole [61-57-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	DTNA MCL1 TOP6BL NEB MECP2 PGR SORBS3 GOLGA2	7.92e-05	197	160	8	5682_DN
Drug	Nizatidine [76963-41-2]; Down 200; 12uM; MCF7; HT_HG-U133A	EPPK1 DTNA PLEKHA6 NEB SPTBN5 ARVCF PCSK6 SORBS3	7.92e-05	197	160	8	5406_DN
Drug	Metanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A	MCL1 NUP210 ZNF516 NECTIN2 PAWR DUSP10 TADA2A GOLGA2	7.92e-05	197	160	8	1515_DN
Drug	Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; PC3; HT_HG-U133A	LRRK1 DBP MECP2 CASZ1 CLCN4 PARD6A HPS4 PLXNA2	7.92e-05	197	160	8	3996_DN
Drug	(R) -Naproxen sodium salt [26159-34-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A	MYLK RTEL1 DTNA GIT2 PLEKHA6 SLC9A1 PCSK6 SORBS3	8.20e-05	198	160	8	6096_DN
Drug	Gossypol [303-45-7]; Down 200; 7.8uM; MCF7; HT_HG-U133A	PDE4A EPPK1 RTEL1 PLEKHA6 CBL PGR PPP1R3C MKI67	8.20e-05	198	160	8	4762_DN
Drug	5155877; Down 200; 10uM; PC3; HT_HG-U133A	RTEL1 DTNA KAT6A LRRK1 SEMA4G HOXB5 HPS4 GOLGA2	8.20e-05	198	160	8	6569_DN
Drug	ICI 182,780; Up 200; 1uM; MCF7; HT_HG-U133A	RTEL1 PRSS16 DTNA SH3BP1 CASZ1 SEMA4G PPP1R3C DUSP10	8.20e-05	198	160	8	6925_UP
Drug	Urosiol [128-13-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	LILRB1 MECP2 MEF2C SEMA4G NUP210 IL17RA NUP160 BRWD1	8.20e-05	198	160	8	7243_UP
Drug	Ald1.1-H_000455; Down 200; 10uM; MCF7; HT_HG-U133A	RTEL1 DTNA YTHDC2 PLEKHA6 SEMA4G HPS4 MACF1 TADA2A	8.20e-05	198	160	8	7516_DN
Drug	15(S)-15-methyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	MYLK RTEL1 PPFIA3 CBL HOXB5 GLI2 HPS4 HERC3	8.20e-05	198	160	8	7526_DN
Drug	Diclofenac sodium [15307-79-6]; Up 200; 12.6uM; MCF7; HT_HG-U133A	PRSS16 GIT2 NEB MEF2C SEMA4G EHBP1L1 ARVCF DUSP10	8.20e-05	198	160	8	7215_UP
Drug	Hexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; MCF7; HT_HG-U133A	PDE4A RTEL1 PRSS16 DTNA GIT2 PLEKHA6 ARVCF IL17RA	8.20e-05	198	160	8	1482_DN
Drug	Pipenzolate bromide [125-51-9]; Down 200; 9.2uM; PC3; HT_HG-U133A	PLXNA3 MEF2A MEF2C SEMA4G HOXB5 SORBS3 TADA2A NUP160	8.49e-05	199	160	8	4484_DN
Drug	Cephapirin sodium salt [24356-60-3]; Up 200; 9uM; HL60; HT_HG-U133A	RTEL1 MARCHF6 MCL1 CARD10 PLEKHA6 CASZ1 HOXB5 PCSK6	8.49e-05	199	160	8	2730_UP
Drug	Gentamicine sulfate [1405-41-0]; Down 200; 2.6uM; PC3; HT_HG-U133A	AMBRA1 NEB CASZ1 PLPPR4 HERC3 IL17RA NUP160 BRWD1	8.80e-05	200	160	8	5883_DN
Drug	Aromatase Inhibitors	PGR MKI67	1.47e-04	3	160	2	ctd:D047072
Drug	diphenylketen	SPIN2A SPIN2B	2.92e-04	4	160	2	CID000013696
Drug	5-DMA	MYLK OGDH SLC9A1	3.04e-04	19	160	3	CID000001793
Drug	geldanamycin	TPR MAP1B KAT6A UBN2 CBL PGR PLPPR4 ERCC6L2 DMD PLXNA2	3.06e-04	371	160	10	ctd:C001277
Drug	Cyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; MCF7; HT_HG-U133A	MAP1B MCL1 GIT2 SLC9A1 ZNF516 PAWR DUSP10	3.31e-04	184	160	7	5340_UP
Drug	2-propylpentanoic acid; Up 200; 10000uM; MCF7; HG-U133A	PDE4A GIT2 DBP SLC9A1 ARVCF SLIT3 DUSP10	3.65e-04	187	160	7	345_UP
Drug	15d-PGJ2; Down 200; 10uM; HL60; HT_HG-U133A	PDE4A CLTCL1 CHD7 SPECC1L MEF2C HPS4 NUP210	4.02e-04	190	160	7	1172_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	TPR MAP1B KAT6A MARCHF6 NEB CBL SPIN1	4.15e-04	191	160	7	4279_DN
Drug	Hydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A	RTEL1 MCL1 GIT2 MECP2 CEP131 IL17RA TADA2A	4.28e-04	192	160	7	4746_DN
Drug	Pyrantel tartrate [33401-94-4]; Down 200; 11.2uM; PC3; HT_HG-U133A	MCL1 YTHDC2 CBL MEF2A CLCN4 SPIN1 BRWD1	4.42e-04	193	160	7	5088_DN
Drug	Cefalonium [5575-21-3]; Down 200; 8.8uM; PC3; HT_HG-U133A	DTNA PPP1R3C SLC9A1 SORBS3 HERC3 NUP160 MTSS2	4.42e-04	193	160	7	4245_DN
Drug	Calycanthine [595-05-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A	KAT6A PPFIA3 PGR KCNB1 ARVCF PARD6A PCSK6	4.42e-04	193	160	7	2764_UP
Drug	Tocopherol (R,S) [10191-41-0]; Down 200; 9.2uM; PC3; HT_HG-U133A	RTEL1 TOP6BL LRRK1 SLC9A1 HPS4 CEP131 NUP160	4.56e-04	194	160	7	6616_DN
Drug	Avermectin B1 [71751-41-2]; Down 200; 4.8uM; MCF7; HT_HG-U133A	RTEL1 DTNA CBL EHBP1L1 ARVCF PCSK6 TADA2A	4.56e-04	194	160	7	6081_DN
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Down 200; 9uM; MCF7; HT_HG-U133A	PDE4A PRSS16 DTNA SEMA4G SLC9A1 NUP210 TADA2A	4.56e-04	194	160	7	5263_DN
Drug	Midodrine hydrochloride [3092-17-9]; Down 200; 13.8uM; PC3; HT_HG-U133A	PLXNA3 EPPK1 AMBRA1 HOXB5 PARD6A TADA2A BRWD1	4.56e-04	194	160	7	2087_DN
Drug	0179445-0000 [211246-22-9]; Down 200; 1uM; MCF7; HT_HG-U133A	MYLK MAP1B RTEL1 OGDH MEF2C EHBP1L1 PARD6A	4.56e-04	194	160	7	4758_DN
Drug	Idoxuridine [54-42-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A	PLXNA3 AMBRA1 TOP6BL PPFIA3 ARVCF SORBS3 YIPF3	4.56e-04	194	160	7	1480_DN
Drug	Cefoperazone dihydrate; Down 200; 5.8uM; MCF7; HT_HG-U133A	RTEL1 TOP6BL PLEKHA6 PPFIA3 SLC9A1 PCSK6 SORBS3	4.70e-04	195	160	7	5424_DN
Drug	Chlorthalidone [77-36-1]; Down 200; 11.8uM; PC3; HT_HG-U133A	PDE4A AMBRA1 TOP6BL CBL CLCN4 PARD6A NECTIN2	4.70e-04	195	160	7	7152_DN
Drug	Dapsone [80-08-0]; Down 200; 16.2uM; PC3; HT_HG-U133A	GIT2 PPFIA3 CBL CASZ1 IL17RA NUP160 PLXNA2	4.70e-04	195	160	7	5078_DN
Drug	Ursolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A	DBP PPFIA3 MECP2 MEF2C EHBP1L1 CEP131 DUSP10	4.70e-04	195	160	7	5825_DN
Drug	H-89, Dihydrochloride; Up 200; 0.5uM; PC3; HT_HG-U133A	GIT2 LRRK1 SEMA4G PPP1R3C NLGN4X PLPPR4 HERC3	4.70e-04	195	160	7	6873_UP
Drug	Monobenzone [103-16-2]; Up 200; 20uM; HL60; HT_HG-U133A	SH3BP1 SEMA4G SPTBN5 SLC9A1 KCNB1 PCSK6 PAWR	4.70e-04	195	160	7	3054_UP
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; MCF7; HT_HG-U133A	MCL1 OGDH EHBP1L1 HPS4 PAWR TADA2A NUP160	4.70e-04	195	160	7	4360_DN
Drug	Amoxapine [14028-44-5]; Down 200; 12.8uM; PC3; HT_HG-U133A	MAP1B NEB MEF2C CLCN4 TADA2A NUP160 BRWD1	4.70e-04	195	160	7	6650_DN
Drug	Cefepime hydrochloride [123171-59-5]; Down 200; 7.4uM; HL60; HT_HG-U133A	TPR RTEL1 DTNA AMBRA1 TADA2A GOLGA2 SON	4.70e-04	195	160	7	6159_DN
Drug	Clorsulon [60200-06-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	DTNA LILRB1 HOXB5 EHBP1L1 HPS4 PCSK6 PLXNA2	4.84e-04	196	160	7	7025_UP
Drug	Pirenzepine dihydrochloride [29868-97-1]; Down 200; 9.4uM; MCF7; HT_HG-U133A	AMBRA1 GIT2 PPFIA3 MECP2 HPS4 TADA2A TOPORS	4.84e-04	196	160	7	7226_DN
Drug	Pregnenolone [145-13-1]; Down 200; 12.6uM; PC3; HT_HG-U133A	MEF2A MEF2C PLPPR4 HPS4 NUP210 CEP131 GOLGA2	4.84e-04	196	160	7	4218_DN
Drug	Estropipate [7280-37-7]; Down 200; 9.2uM; PC3; HT_HG-U133A	DBP NEB CASZ1 SEMA4G HOXB5 NUP210 TADA2A	4.84e-04	196	160	7	4472_DN
Drug	Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	RTEL1 DTNA MARCHF6 SEMA4G PGR HOXB5 EHBP1L1	4.84e-04	196	160	7	5280_DN
Drug	Pentamidine isethionate [140-64-7]; Down 200; 6.8uM; HL60; HT_HG-U133A	DTNA MCL1 LRRK1 PPP1R3C CLCN4 HERC3 NUP160	4.84e-04	196	160	7	2473_DN
Drug	Diflorasone Diacetate [33564-31-7]; Down 200; 8uM; MCF7; HT_HG-U133A	AMBRA1 YTHDC2 PLEKHA6 PPP1R3C SLC9A1 PCSK6 TADA2A	4.84e-04	196	160	7	2798_DN
Drug	Nomifensine maleate [32795-47-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	LRRK1 CLCN4 GLI2 HPS4 NUP210 SORBS3 IL17RA	4.84e-04	196	160	7	5863_UP
Drug	Alprenolol hydrochloride [13707-88-5]; Down 200; 14uM; PC3; HT_HG-U133A	MECP2 HOXB5 CLCN4 HPS4 NUP160 GOLGA2 BRWD1	4.84e-04	196	160	7	7141_DN
Drug	Suxibuzone [27470-51-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	PDE4A MYLK DTNA PPP1R3C PCSK6 NUP210 SORBS3	4.84e-04	196	160	7	6065_DN
Drug	Netilmicin sulfate [56931-57-2]; Down 200; 2.8uM; HL60; HT_HG-U133A	DTNA LILRB1 MEF2A SLC9A1 EHBP1L1 PCSK6 GOLGA2	4.84e-04	196	160	7	2963_DN
Drug	Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	MYLK DTNA KAT6A MARCHF6 AMBRA1 EHBP1L1 PCSK6	4.84e-04	196	160	7	3256_UP
Drug	Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; PC3; HT_HG-U133A	DTNA LRRK1 MECP2 SORBS3 DUSP10 GOLGA2 MTSS2	4.84e-04	196	160	7	4227_DN
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	RTEL1 NEB GLI2 HERC3 GPNMB TAL1 PLXNA2	4.84e-04	196	160	7	5088_UP
Drug	Carisoprodol [78-44-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A	YTHDC2 GIT2 PLEKHA6 DBP MECP2 NUP210 SORBS3	4.84e-04	196	160	7	3251_DN
Disease	Autism Spectrum Disorders	MEF2C NLGN3 NLGN4X USH2A TET3 UNC80	6.37e-06	85	157	6	C1510586
Disease	autism spectrum disorder (implicated_via_orthology)	CHD7 MEF2A MEF2C NLGN3 NLGN4X ARVCF	1.69e-04	152	157	6	DOID:0060041 (implicated_via_orthology)
Disease	monocyte count	TOM1L2 PAG1 LILRB3 ARHGAP23 MCL1 PLEKHA6 CBL OGDH SHC3 MEF2C CASZ1 ARVCF CIITA ZNF516 IL17RA TADA2A ATP1A4 DNMT1	2.43e-04	1320	157	18	EFO_0005091
Disease	interleukin-17 receptor A measurement	IL17RA TADA2A	2.78e-04	5	157	2	EFO_0801718
Disease	quality of life during menstruation measurement, breast pressure measurement	MAP1B ANKRD17	4.16e-04	6	157	2	EFO_0009366, EFO_0009393
Disease	Autism spectrum disorder	MECP2 NLGN4X	5.80e-04	7	157	2	cv:C1510586
Disease	familial hemiplegic migraine (implicated_via_orthology)	ATP1A4 ATP4A	5.80e-04	7	157	2	DOID:0060178 (implicated_via_orthology)
Disease	osteopetrosis (implicated_via_orthology)	LRRK1 CLCN4	5.80e-04	7	157	2	DOID:13533 (implicated_via_orthology)
Disease	Mental Retardation, X-Linked 1	MECP2 CLCN4 DMD	6.54e-04	32	157	3	C2931498
Disease	Ventricular Dysfunction	IGF2R DMD	7.71e-04	8	157	2	C0242973
Disease	Schizophrenia	PAG1 PDE4A PRSS16 AMBRA1 PLEKHA6 LILRB1 KCNB1 ARVCF HPS4 SLIT3 PAWR PLXNA2 DNMT1	9.17e-04	883	157	13	C0036341
Disease	type 2 diabetes mellitus (biomarker_via_orthology)	NCOA6 SLC9A1 MKI67 DNMT1 ATP5F1B	1.16e-03	147	157	5	DOID:9352 (biomarker_via_orthology)
Disease	lung cancer (is_marker_for)	MCL1 MKI67 DNMT1	1.17e-03	39	157	3	DOID:1324 (is_marker_for)
Disease	visual epilepsy (biomarker_via_orthology)	PDE4A MAP1B MECP2 PAWR	1.38e-03	90	157	4	DOID:11832 (biomarker_via_orthology)
Disease	autistic disorder (is_implicated_in)	MECP2 NLGN3 NLGN4X	1.46e-03	42	157	3	DOID:12849 (is_implicated_in)
Disease	interleukin 17 receptor A measurement	IL17RA TADA2A	1.50e-03	11	157	2	EFO_0008175
Disease	myeloid white cell count	ARHGAP23 UBQLN4 SH3BP1 CHD7 LRRK1 ARVCF ZNF516 PAWR IL17RA TADA2A ATP1A4 NUP160 DNMT1	1.56e-03	937	157	13	EFO_0007988
Disease	nervous system disease (implicated_via_orthology)	ATP1A4 ATP4A	1.79e-03	12	157	2	DOID:863 (implicated_via_orthology)
Disease	coronary artery disease	NCOA6 CLTCL1 MAP1B MCL1 SPECC1L EHBP1L1 IGF2R ARVCF KIAA1217 NUP210 PAWR LRRC7 FGD5 CORO7 NUP160	1.83e-03	1194	157	15	EFO_0001645
Disease	Malignant neoplasm of breast	AKAP6 NCOA6 PGR NSUN6 CHD5 NECTIN2 HEATR9 MKI67 MACF1 LRRC7 FGD5 GPNMB DMD DNMT1	1.85e-03	1074	157	14	C0006142
Disease	complement factor H-related protein 3 measurement	AKAP6 PLEKHA6 DMD USH2A SDK1	2.15e-03	169	157	5	EFO_0600056
Disease	cholesterol in medium LDL measurement	SNX17 IGF2R NECTIN2	2.28e-03	49	157	3	EFO_0022224
Disease	cholesterol in small LDL measurement	SNX17 IGF2R NECTIN2	2.28e-03	49	157	3	EFO_0022227
Disease	total lipids in medium LDL	SNX17 IGF2R NECTIN2	2.70e-03	52	157	3	EFO_0022180
Disease	Intellectual Disability	AKAP6 MAP1B KDM3B SPECC1L MECP2 MEF2C MACF1 TET3	2.80e-03	447	157	8	C3714756
Disease	health literacy measurement	PAG1 SH3BP1 PERM1	2.85e-03	53	157	3	EFO_0010104
Disease	cholesterol in small VLDL measurement	SNX17 IGF2R NECTIN2	2.85e-03	53	157	3	EFO_0022228
Disease	Barrett Epithelium	MCL1 SLC9A1	3.21e-03	16	157	2	C1258085
Disease	Barrett Esophagus	MCL1 SLC9A1	3.21e-03	16	157	2	C0004763
Disease	Carcinoma, Granular Cell	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0205644
Disease	Adenocarcinoma, Tubular	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0205645
Disease	Adenocarcinoma, Oxyphilic	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0205642
Disease	Carcinoma, Cribriform	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0205643
Disease	Adenocarcinoma, Basal Cell	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0205641
Disease	Adenocarcinoma	PGR MKI67 PAWR DNMT1	3.48e-03	116	157	4	C0001418
Disease	Endometrial Neoplasms	PLXNA3 PGR PAWR	3.68e-03	58	157	3	C0014170
Disease	creatine kinase measurement	AKAP6 NEB GPNMB	3.86e-03	59	157	3	EFO_0004534
Disease	cortical surface area change measurement, age at assessment	PCSK6 NECTIN2	4.53e-03	19	157	2	EFO_0008007, EFO_0021503
Disease	Meningioma	TRAF7 PGR	4.53e-03	19	157	2	C0025286
Disease	esterified cholesterol measurement	IGF2R NECTIN2 ANKRD17 NUP160	4.94e-03	128	157	4	EFO_0008589
Disease	lymphocyte count	PDE4A EPPK1 CARMIL2 CHD7 PLEKHA6 DBP CBL CASZ1 ARVCF NECTIN2 ERCC6L2 TADA2A KLHL14 CORO7 NUP160 DNMT1	5.10e-03	1464	157	16	EFO_0004587

Protein segments in the cluster

Peptide	Gene	Start	Entry
EMTLPSDPERATLPN	BRWD1-AS2	111	P59051
REEDPAPPKRSFSSM	CARD10	536	Q9BWT7
PMSEAVGSPSERLRA	CCDC17	126	Q96LX7
LADERPAFPMVTAPL	ARVCF	311	O00192
TRLPSMLSRIPPVAA	CHD5	1876	Q8TDI0
MPARTAPARVPTLAV	DNMT1	1	P26358
AAASVPAPPASIMER	CASZ1	851	Q86V15
DLPSMPEPALTSRAN	CIITA	296	P33076
PTPASMLARLERSSP	CARMIL2	131	Q6F5E8
RAPETASAPLSMDDP	ARHGEF5	551	Q12774
PDRDPASPLRMANSA	GPNMB	486	Q14956
PPETAAPVEDMARRT	SH3BP1	551	Q9Y3L3
PPARSREPDMETLIL	AJM1	861	C9J069
SSASRPASLPRVPAM	SPECC1L	921	Q69YQ0
ASRPEESRMRLQPFP	GIT2	531	Q14161
ATDVMRPRRGEPPLS	CLCN4	596	P51793
MPTSPQSPRDAELIA	DMD	3546	P11532
PMVLSLVVPSAERSP	DNHD1	1306	Q96M86
LNSRSEAESMPPPRT	AMBRA1	426	Q9C0C7
PEVRMTVPPLATSSA	ANKRD17	2131	O75179
MSREPETERVERPPA	CHD7	936	Q9P2D1
PAVDPLDSTSRIMDP	ATP5F1B	396	P06576
PSRDPETPRSSGSMR	CDCA3	171	Q99618
RASTMPRLDPPEDKT	RBM22	216	Q9NW64
AMLTRAAPGPRRSED	PAWR	96	Q96IZ0
PSRPIVPLSSRSMEI	KIAA1549	486	Q9HCM3
EERPRPQFAASAPMT	ANO7	461	Q6IWH7
STRPVLASIEPELPM	NUP210	811	Q8TEM1
RMYSLRPEPPDTGVS	FAM47C	566	Q5HY64
RTPEPSPLRAESHMQ	LPIN3	231	Q9BQK8
STPMASPDLLPEDVR	IL17RA	731	Q96F46
RDTAELPARTSPMPG	PTPRN	396	Q16849
PSRVDSMPLTEAPAF	MYLK	21	Q15746
QDRSPSPRHPDVSMV	MAP1B	2206	P46821
EPQREPPTTSAAAAM	MAGEB4	61	O15481
SMGARVDLEPVSPRS	NCKAP5L	756	Q9HCH0
MSRPLLITFTPATDP	GPANK1	1	O95872
IPQRPDRLPMSDTFT	LRRC7	751	Q96NW7
SPLRDMFPVRPLDTE	LRRK1	1781	Q38SD2
IPQLSSSPPDVEAMR	HERC3	491	Q15034
TELSMLEPDPRSPFA	HMCN2	4996	Q8NDA2
PPTPRSARLERMTQA	PPFIA3	716	O75145
PEEATPSSRPNRMAS	JPT2	31	Q9H910
MSEAVRVPSPATPLV	HECTD2	1	Q5U5R9
AISSLRPPSAPEMLT	HPS4	421	Q9NQG7
MPPSPLDDRVVVALS	DUSP10	1	Q9Y6W6
DMSPVSQAPREAPAR	CORO7	861	P57737
RSRMLELSAPELEPP	PCSK6	646	P29122
PDSLRSRAPMITPDL	PLXNA2	1631	O75051
SSPDSLRSRAPMITP	PLXNA3	1606	P51805
PDSLRSRTPMITPDL	PLXNA4	1631	Q9HCM2
SEEIQRAFAMPAPTP	NXF1	541	Q9UBU9
EAPRPRMSPATIAAK	MTSS2	421	Q765P7
MEPPTVPSERSLSLS	PDE4A	1	P27815
MRERPVSMSFPLSSP	FGD5	1311	Q6ZNL6
PPETSPEMRSSRQPA	EHBP1L1	281	Q8N3D4
ESMPTLTPAFPRSLL	KDM3B	596	Q7LBC6
QDPEPRSMTLDSPRA	KIAA2012	741	Q0VF49
SPDMPSRLPIQDIFA	MARCHF6	66	O60337
TPMPRDGLRNPETAS	MIGA2	206	Q7L4E1
RPSPDERESPSVKRM	MEF2C	451	Q06413
PRPPSISENVAMEAV	GLI2	1026	P10070
LEMPRASTPRPLTVT	KIAA1549L	761	Q6ZVL6
PRREMASPPSSLSGE	LILRB3	551	O75022
PPPESMDTPTSTRRR	MKI67	2106	P46013
PPNTEDRESPSVKRM	MEF2A	486	Q02078
PSAVPLPDTDMDSLR	NSUN6	426	Q8TEA1
RLPPRPAMSEETRQS	GOLGA2	6	Q08379
RPSALEADSPMAPKR	KIF18B	631	Q86Y91
SSRLRMPPLIPAEVD	MACF1	5911	Q9UPN3
RAQPEPMATSTAAPE	HOXB5	156	P09067
MARPQRTPARSPDSI	PARD6A	1	Q9NPB6
RTPRPASQSDAMDPL	NCOA6	206	Q14686
DAPMAPGRSPLATTV	PGR	286	P06401
DSDSERPMPRLEPTF	KAT6A	1051	Q92794
LRRSPDDIPLMTPNT	NLGN3	796	Q9NZ94
DPRMARSSPYPTDVA	OGDH	451	Q02218
LPESRAPDMSPQRIS	RBBP8NL	201	Q8NC74
PLNRFSSVPLDPMER	CBY2	91	Q8NA61
MAPPSTREPRVLSAT	EXOSC10	1	Q01780
RPQDPLVAPMTESSA	FHAD1	971	B1AJZ9
RPMPSVPEDLESREA	GOLGA8DP	236	Q0D2H9
MRALLDSLPPPVESE	KLHL14	221	Q9P2G3
RSTSSLPPEPMEIVR	KCNB1	11	Q14721
SSRDNIVDLMSLPPP	FRMPD3	666	Q5JV73
MAPVPLDDSNRPASL	BCLAF1	551	Q9NYF8
PEPALDSTMRAAPQD	ANKS6	491	Q68DC2
MAEPSSARRPVPLIE	BRWD1	1	Q9NSI6
RPIPMPIRSASACST	DTNA	571	Q9Y4J8
MDTAYPREDTRAPTP	IFITM5	1	A6NNB3
DMARRSAPERPSAAE	KNDC1	561	Q76NI1
MARPVSDRTPAPLLL	DBP	1	Q10586
SQMEPRPDVPRLGST	CBL	626	P22681
EDTEYMTPSSRPLRP	CBL	696	P22681
MTPSSRPLRPLDTSQ	CBL	701	P22681
PDALRMISNADPSIP	EPS8	196	Q12929
RMDPSAPQPRAETSG	ERCC6L2	11	Q5T890
TPVQPMTRRLFDPET	C4orf54	1626	D6RIA3
PIARAPRGSELSPMV	C4orf54	1696	D6RIA3
AETSRLMLPEEPPSA	SDK1	756	Q7Z5N4
RSGSPRPTEPTDFLM	CEP131	86	Q9UPN4
RSPDDIPLMTPNTIT	NLGN4X	766	Q8N0W4
ASSPPVSEAVPRMTE	PERM1	426	Q5SV97
SMIDPPRATVPDAVL	ATP4A	601	P20648
LESMLTPPIARRVPF	FANCD2	976	Q9BXW9
PTRRAAPLEEMEAPA	MCL1	101	Q07820
ESHLIVPETRPSPRM	OR13A1	6	Q8NGR1
IVSSSMPRPNREEPV	MECP2	461	P51608
MRTAAGAVSPDSRPE	NRAC	1	Q8N912
PEARPTNRPMLISLD	IGF2R	1616	P11717
VAERTMPAPAPRATA	RTEL1	751	Q9NZ71
TNRPDTLDPALMRPG	PSMC2	321	P35998
STRPPRMPSASAEFV	USH2A	1996	O75445
MERSPDVSPGPSRSF	TRIM35	1	Q9UPQ4
DLLDLSPSPRMPRAT	TOM1L1	316	O75674
DPRPLTSSVMPVDVA	PPP1R3C	11	Q9UQK1
EEMRALRSARAPSPS	TOP6BL	501	Q8N6T0
DPPRPTFDSLLSRDM	TADA2A	151	O75478
PTSQEAPPVREMTLR	LRRC27	181	Q9C0I9
RREMASPPSPLSGEF	LILRB1	571	Q8NHL6
MTERPPSEAARSDPQ	TAL1	1	P17542
PRPDPREALRAATME	EPPK1	3576	P58107
PRPDPREALRAATME	EPPK1	4646	P58107
MAAPEAPPLDRVFRT	KNSTRN	1	Q9Y448
SAPSAPRAPAMSAAR	SHC3	111	Q92529
PPASPHRVSDLRMID	KIAA1217	471	Q5T5P2
LRIMPESSESPPTER	SPIN2A	186	Q99865
MPTAIRGDQSPSDRP	NUP160	271	Q12769
RELPRIPPESAVDTM	PAG1	131	Q9NWQ8
AQMDTSPAPRSPVEA	SPTBN5	2491	Q9NRC6
SPAPRSPVEARRMLE	SPTBN5	2496	Q9NRC6
MSRSTPSLVDPPDRS	AKAP6	421	Q13023
EPAPLTLTSPRMVAA	ANKHD1	2101	Q8IWZ3
SMIDPPRAAVPDAVS	ATP1A4	596	Q13733
SDPMAPIRRPISAES	CLTCL1	56	P53675
SAPRTGSIRPPDSLM	C12orf54	76	Q6X4T0
SPEPMADRLLLTTPT	SLIT3	886	O75094
PPLLESPDATRESMV	SNX17	416	Q15036
QSPPRSIEMRSSSEP	PLPPR4	471	Q7Z2D5
NMVSEVPPERPSVRA	PLEKHA6	21	Q9Y2H5
MPLDLSARSTRDDPS	ZNF516	731	Q92618
MRGAASASVREPTPL	ZFP28	1	Q8NHY6
TRTLPMSPPSERVQE	ZBTB5	121	O15062
EVSRAEPPMSLQREP	UBN2	76	Q6ZU65
PLLPRPRSSSMVAAA	UNC80	376	Q8N2C7
PSRELDATPRMTIPY	SEMA4G	26	Q9NTN9
EVARPASTPPIMASA	SRCIN1	1061	Q9C0H9
STPRASIRPMVTPAT	TPR	1691	P12270
RIMPDSNDSPPAERE	SPIN1	191	Q9Y657
APPARASTRATMVPE	ARHGAP23	196	Q9P227
RPPAAALASRPSRME	ARHGAP23	1356	Q9P227
LRIMPESSESPPTER	SPIN2B	186	Q9BPZ2
SEMRSRPLEPTQDPL	HEATR9	131	A2RTY3
RDEEDSMPPISTPRR	TRAF7	71	Q6Q0C0
SMPPISTPRRSDSAI	TRAF7	76	Q6Q0C0
LDSPTMSRARIGSDP	SLC9A1	691	P19634
SPESESPMLRITAPL	SEZ6	141	Q53EL9
GMPIAPRSSVDRPRD	SORBS3	131	O60504
MARTAPVEPPLRHSA	PPP1R3F	1	Q6ZSY5
RPPSEMADFLSDAIP	TBC1D15	271	Q8TC07
PSRDSLLPPTQEMRS	TET3	671	O43151
AMPPEARTSFPLSES	YY1AP1	531	Q9H869
GQRPRPMSSEELPLA	YTHDC2	1176	Q9H6S0
DIPAMLPAARLPTTV	YIPF3	321	Q9GZM5
APARPAPASSEIMAS	TOPORS	56	Q9NS56
EPSRQLPSPRTSLMS	TOPORS	1021	Q9NS56
QRSVPEVDPAATMPR	TOM1L2	166	Q6ZVM7
MAEPSGAETRPPIRV	UBQLN4	1	Q9NRR5
MSRAPSEIDPRENPD	TTC4	46	O95801
MAPERPSDSPSLRLG	PRSS16	476	Q9NQE7
ADSSMTRPQELPELP	SON	351	P18583
RKATPTPVTPEMERA	NEB	6376	P20929
MARAAALLPSRSPPT	NECTIN2	1	Q92692